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Multidrug-resistance in Gram-negative bacteria that produce either extended-spectrum 
beta-lactamases (ESBLs) or carbapenemases is a public health concern due to the 
limited availability of treatment options. Their actual prevalence in healthy human in 
the community settings is largely unknown and possibly underestimated. This study 
aimed to determine their prevalence and genetic characteristics in stools from healthy 
infants of less than one year of age and their mothers, and to determine the risk factors 
associated with their carriage. 
This pilot study was nested within an ongoing longitudinal prospective birth-cohort 
study, the Drakenstein Child Health Study (DCHS), located in the Drakenstein sub-
district, Western Cape Province, South Africa. The study was approved by the Faculty of 
Health Sciences (FHS) Human Research Ethics Committee (HREC) of the University of 
Cape Town, South Africa (HREC reference number: 738/2013).  
This work was funded by the Bill and Melinda Gates Foundation Global Health Grant 
(OPP107641), the Wellcome Trust (United Kingdom), the Carnegie Corporation of New 
York (United States of America), and the National Research Foundation (South Africa). 
Any opinions, findings and conclusions, or recommendations expressed in this 
dissertation are those of the author, and therefore do not represent the official position 
of the funders. 
This thesis was written in a monograph format, and supervised by Dr Mamadou Kaba 
and Prof Mark Nicol. It consists of scientific contributions or publications co-authored 
by the MSc candidate. This thesis includes an abstract, general introduction (including 
the rationale, aim, and objectives), literature review, the methods, the results, 
discussion, and conclusion and future direction. 
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Abstract 
Background: The prevalence of extended-spectrum beta-lactamase (ESBL) - and 
carbapenemase-producing Enterobacteriaceae in healthy humans in the community is 
largely unknown.  We aimed to determine the prevalence and genetic characteristics of 
ESBL- and carbapenemase-producing Enterobacteriaceae in stools from healthy infants 
and their mothers, and to determine the risk factors associated with their carriage.  
Methods: This study was nested within the Drakenstein Child Health Study, a birth 
cohort in a semi-rural region of Western Cape Province, South Africa. Maternal and 
infants faecal samples (including the meconium) were collected at birth and at two 
additional time-points (5-12 and 20-28 weeks) from the infants only. Samples were 
screened for ESBLs and carbapenemase-producing organisms using ChromID ESBL and 
ChromID CARBA media, respectively. Identification of suspect ESBL/carbapenemase-
producing isolates and antibiotic susceptibility were determined using the Vitek 2 
system. ESBL production was confirmed using the combination disc test, and that of 
carbapenemase using the modified hodge test. Selected ESBL and carbapenemase genes 
were evaluated by the singleplex conventional polymerase chain reaction and Sanger 
sequencing. Risk factors were assessed by univariate analysis using the EPI Info version 
7 software.  
Finding: We screened 193 stool and 116 meconium samples. Maternal faecal carriage 
of ESBL-producing organisms was 4.4%; 4/90 (95% confidence interval (CI): 1.5% - 
10.2%), and that of infants at birth was 3.5%; 4/116 (95% CI: 1.2% - 8.0%). The infant 
faecal carriage of ESBL-producing organisms at 5-12 and 20-28 weeks was 4.4%; 3/68 
(95% CI: 1.3% - 11.3%) and 5.7%; 2/35 (95% CI: 1.2% - 17.1%), respectively. ESBL 
genes were detected in six K. pneumoniae (blaCTX-M-15), five E. cloacae (blaSHV-12 (n= 3) 
and blaSHV-5 (n= 2)) and three E. coli (blaCTX-M-14) isolates. All stool samples tested 
negative for carbapenemase-producers. Pulsed-field gel electrophoresis showed 
heterogeneous clones of CTX-M-15-producing K. pneumoniae isolates. In contrast, we 
observed clonal relations among ESBL-producing E. cloacae isolates. One mother-infant 
pair was ESBL-positive at birth with SHV-5- producing E. cloacae. In addition, one infant 
was persistently colonized by SHV-12-producing E. cloacae isolate. Infants born to HIV-
positive mother, via elective caesarean section, and medication use before discharge 
were positively associated with ESBL faecal carriage. In contrast, breastfeeding prior to 
discharge was negatively associated with ESBL carriage. 
Interpretation: This is the first study to detect ESBL-producing bacteria in human 
meconium samples in Africa, and raises questions on the source of such isolates and 
implications for community transmission. Faecal carriage of ESBL-producing bacteria 
was common in our study area. Carbapenemase-producing organisms were not 
detected in stool samples tested. Further research or continuous surveillance is 
important in order to anticipate future trends in the dissemination of ESBL- and 






1.1 Problem identification 
Multidrug-resistance is emerging worldwide at an alarming rate among Gram-negative 
bacteria causing both community-acquired and nosocomial infections.1,2 One of the 
most important emerging resistance profiles in bacteria belonging to the 
Enterobacteriaceae family corresponds to resistance to extended-spectrum beta-
lactams and carbapenems.2–4 The major reservoir for such bacteria is the 
gastrointestinal tract.5 Prior gastrointestinal colonization by multidrug resistant 
bacteria has been associated with subsequent infection.6 A study in the United States of 
America (USA) has emphasized the importance of identifying individuals carrying 
antimicrobial-resistant bacteria in both patient and healthy populations.7 Another study 
reported that an increase in the proportion of carriage of antimicrobial-resistant 
bacteria in the community increases the risk that other individuals will also become 
carriers via human-to-human transmission.8–10 In addition, the admission into hospital 
of patients harboring resistant bacteria increases the risk of other hospitalized patients 
contracting an infection.8,11,12  
The actual prevalence of extended-spectrum beta-lactamase (ESBL) - and 
carbapenemase-producing organisms in healthy humans in the community settings is 
largely unknown and possibly underestimated.13,14 The acquisition of antibiotic 
resistance genes at birth has been recently reported, with the mode of delivery affecting 
rates of acquisition,15,16 however most studies on the community carriage of 
antimicrobial-resistant bacteria have been cross-sectional, and targeted adult 
populations.14,17–21 In addition, few longitudinal birth-cohort studies describing the 
acquisition of ESBL- and carbapenemase-producing organisms have been conducted 
worldwide.22,23 Therefore, the aim of this project was to study the epidemiology and 
genetic characteristics of ESBL- and carbapenemase-producing bacteria in stool 
samples from apparently healthy children of less than one year of age and their 
mothers, and to determine the risk factors associated with their acquisition.  
1.2 Rationale and motivation 
Multidrug-resistance in Gram-negative bacteria is a public health concern due to the 





Gram-negative bacteria that produce either extended-spectrum beta-lactamases 
(ESBLs) or carbapenemases has been increasingly reported over the past years, both in 
hospitals and communities worldwide.3,4 The microorganisms producing ESBLs may be 
responsible for infections that are life-threatening, thus resulting in increased 
healthcare-associated costs, morbidity and mortality.26 The first line drugs for the 
treatment of severe infections caused by ESBL-producing bacteria are the 
carbapenems,27 however their efficacy is highly compromised by the emergence and 
spread of carbapenemase-producing bacteria worldwide.28,29 The strains that produce 
either carbapenemases or ESBLs often carry resistance determinants for other classes 
of antimicrobial agents, and infections caused by these strains are associated with high 
mortality.30–32  
A major concern is the coexistence of multiple ESBL and carbapenemase genes that has 
led to the emergence of organisms that are resistance to nearly all antibiotics.33 The 
situation is also complicated by the emergence of a novel carbapenemase, the New Delhi 
Metallo-beta-lactamase 1 (NDM-1).34,35 NDM-1-producing bacteria are highly resistant 
to almost all beta-lactam antibiotics.34 The blaNDM-1 gene is carried on the large plasmids 
and is increasingly discovered in diverse bacteria.36–41 Most organisms producing NDM-
1 co-produce the extended-spectrum beta-lactamase CTX-M-15.13  The identification of 
NDM-1 in Escherichia coli sequence type 131 (ST 131) as a source of community-
acquired infection is more concerning.42 E. coli ST-131 is known to effectively mobilize 
the ESBL CTX-M-15 worldwide.43  
The epidemiology of ESBL- and carbapenemase-producing organisms has been 
described in considerable detail in certain parts of the world.30,32,44 The emergence of 
ESBLs and that of carbapenemases has had different epicenters, but they are now 
widespread worldwide.13,41,45 ESBLs became apparent almost simultaneously in Europe 
and South America, whereas carbapenemases emerged mainly in Asia, Europe and 
North America.13,45  ESBLs have spread widely geographically, causing outbreaks in 
many parts of the world,32 and this is likely to be the case with carbapenemases.45 The 
prevalence of ESBLs and carbapenemases in the community varies depending on 
geographical location.46,47 For example, in community settings, the prevalence of ESBLs 





Senegal.49 The prevalence of bacteria harboring carbapenemases in the community is 
largely unknown.13 
In Africa, data on the prevalence of ESBL- and carbapenemase-producing 
Enterobacteriaceae remain scarce and only few studies have been conducted in the 
community or hospital settings during non-outbreak situations.41,49–52 For instance, a 
study in a Moroccan hospital showed a prevalence of 13% faecal carriage of OXA-48-
carbapenemase producing Enterobacteriaceae among hospitalized patients.50 A study in 
Niger found ESBL-producing Enterobacteriaceae carriage of 31% within 24h of 
hospitalization among 55 children,53 while a study in Gabon found a prevalence of 
33.6% of ESBL-producing Enterobacteriaceae within 48h of hospitalization in 110 
children, reflecting the likely faecal carriage of ESBL-producing Enterobacteriaceae in 
community settings.54 In addition, 2 out of 20 children with no known antibiotic 
exposure living in a very remote Senegalese village were found to be faecal carriers of a 
multiresistant Escherichia coli clone that produced CTX-M-15, highlighting the spread of 
ESBLs even in isolated communities.49  
Colonization of the gastrointestinal tract by resistant organisms has been associated 
with a high risk for developing infection due to these organisms.6,44  Several risk factors 
have been found to be associated with ESBL and carbapenemase carriage, which include 
prolonged hospitalization, prolonged ICU stay, multiple hospitalization, invasive 
devices, immunosuppression and recent antibiotic treatment.55–57 Other risk factors for 
ESBL rectal carriage are old age (older than 65 years), female sex and MRSA carriage.57 
In the community, risk factors are still not clear but factors that enhance the spread of 
these organisms include lack of hygiene, overuse and over-the-counter use of 
antibacterial drugs, and increased worldwide travel.13 
To date, only few studies have been conducted on ESBL- and carbapenemase-producing 
bacteria in apparently healthy populations in Africa.49,54 Carbapenemase- and ESBL-
producing bacteria have been shown to be circulating in hospitals in South 
Africa,50,55,58,59 Therefore, this study aimed to determine the prevalence and risk factors 
associated with the acquisition of both extended-spectrum beta-lactamase- and 
carbapenemase-producing bacteria in stool samples from apparently healthy children 





assessed mother-to-infant transmission of ESBL- and carbapenemase-producers. 
Finally, the characterization of resistance genes provided some data on the resistance 
genes circulating in the study area. 
1.3 Aim and objectives 
1.3.1 The aim 
This study aimed to study the epidemiology and genetic characteristics of ESBL- and 
carbapenemase-producing bacteria in stool samples from of apparently healthy South 
African children and their mothers. 
1.3.2 Specific objectives 
• To determine the prevalence of ESBL- and carbapenemase-producing 
Enterobacteriaceae in stool samples from apparently healthy children of less than 
one year of age and their mothers and risk factors associated with their acquisition. 
• To characterize the ESBL and carbapenemase genes from ESBL- and 
carbapenemase-producing isolates. 
• To investigate the genetic relatedness of the ESBL- and carbapenemase-producing 
isolates within infant-mother pairs. 










2. A review on the epidemiology of extended-spectrum beta-lactamase- and 
carbapenemase-producing bacteria 
The epidemiology of ESBL- and carbapenemase-producing organisms has been 
substantially described in Europe, North America and Asia.13,45,60–62 Little is known 
about their epidemiology in Africa, however, their prevalence is increasingly reported in 
both hospital and community settings.41,63,64 Therefore, this review gives an overview of 
the epidemiology of ESBL- and carbapenemase-producers in Africa. In addition, it aimed 
to identify research gaps regarding the study of ESBL- and carbapenemase-producing 
bacteria.  
2.1 An overview of antibiotic resistance 
2.1.1 Discovery and occurrence of antibiotic resistance 
Long before the discovery of penicillin by the British scientist Alexander Fleming in the 
late 1920s, infectious diseases were the leading cause of mortality worldwide.65,66 The 
introduction of penicillin in the 1940s and together with vaccination resulted in 
improved life expectancy and reduced mortality rate due to infectious diseases during 
the 20th century.65,67 However, soon after its introduction penicillin-resistant  
Staphylococcus aureus was detected.68 The resistance to penicillin was due to bacterial 
production of penicillinase, a beta-lactamase enzyme capable of hydrolysing 
penicillin.68,69 Other antibiotics such as tetracycline, streptomycin and chloramphenicol 
were introduced in the late 1940s, likewise resistance to these antibiotics was also 
noted soon after their introduction.70 
Antibiotic resistance, defined as the ability of bacteria to resist the effects of 
antibacterial drugs, is one of the world’s most pressing public health threats.70,71 
Infections caused by multidrug-resistant (MDR) organisms are increasingly reported 
worldwide,1,2,72,73 with very limited treatment options.74  Lack of effective treatment of 
patients infected with MDR organisms has led to high mortality and morbidity rates.74 
The rate of novel antibiotic discovery is currently very low compared to the increasing 
resistance problem.75 However, it is worth mentioning that a novel antibiotic under 
development (phase I clinical trial) shows potential for treatment of multidrug-resistant 





resistance to antibiotics makes it difficult to develop or discover effective 
antibiotics.74,75   
2.1.2 Mechanisms of antibiotic resistance 
Resistance can be either an inherent trait of the bacterium (intrinsic) or acquired.77 A 
variety of bacterial species possess intrinsic resistance through inherited mechanisms.78 
Some bacteria can mutate to highly resistant forms, however, this accounts for a small 
proportion of antibiotic resistance.70 Most bacteria become resistant to antibiotics 
through the acquisition of resistance-conferring deoxyribonucleic acid (DNA) from 
other sources.78–81 Antibiotic resistance genes can be carried on a plasmid, 
chromosome, or transposon; however, most of these genes are encoded or carried on 
plasmids, which are self-replicating extrachromosomal pieces of DNA (and which may 
themselves carry transposons).78,82–84 Transposons are non-self-replicating pieces of 
genetic material that can be easily exchanged between plasmid and plasmid, 
chromosome and chromosome, or between plasmid and chromosome.82 Transposons 
also play a major role in disseminating resistance genes among bacterial species.78,83,84 
Resistance genes can be spread from one bacterial species to another by conjugation, 
transformation, or transduction.85 Plasmids can transfer genetic material through 
conjugation.82 Transduction is a process in which a bacteriophage is needed for 
exchange of genetic material; whereas, transformation is the uptake of free DNA from 
the environment.78–80,83,85  
Bacterial resistance to antibiotics can be caused by either the enzymatic modification of 
an antibiotic which renders it ineffective, the modification of its target site so that it is 
unable to exert its effect, active physical removal of the antibiotic from the cell, or by 
reduction of uptake into the bacterial cell due to changes in membrane 
permeability.78,86,87 The main resistance mechanism is the enzymatic inactivation of an 
antibiotic and the most clinically important example of this is beta-lactamase enzymes, 
the enzymes that hydrolyze beta-lactam antibiotics.88,89 This review will focus beta-






2.2.1 Classification of beta-lactams 
Beta-lactams are a broad class of antibiotics that are widely used for treating bacterial 
infections.90 All antibiotics in this class contain, in their molecular structure, a beta-
lactam ring which is a four membered lactam (cyclic amide) (Figure 1).91,92 Beta-lactam 
antibiotics include: the penicillins, cephamycins, cephalosporins, monobactams, 
carbapenems and beta-lactamase inhibitors.90,92  
 
 
Figure 1. Diagram showing the core structure of penicillin and beta-lactam ring.  
The beta-lactam ring is the active site of the beta-lactam antibiotics that irreversibly bind to the penicillin-
binding proteins (PBPs) thus blocking their action of synthesizing a peptidoglycan layer. This leads to the 
weakened bacterial cell wall; and the bacterium eventually bursts.93 
2.2.1.1Penicillins 
Penicillins are effective against most Gram-positive and some Gram-negative strains.94 
Several types of penicillins exist; the natural penicillins (penicillin G), penicillinase-
resistant penicillins (e.g. methicillin and oxacillin) and aminopenicillins (e.g. ampicillin 
and amoxicillin).94–97 The first two types of penicillins have lethal effects on many Gram-
positive organisms, whilst aminopenicillins are effective against a wider range of 





2.2.1.2 Cephalosporins and cephamycins 
Cephalosporins are subdivided into five generations including the closely related 
cephamycin compounds and together they constitute a group of beta-lactams called 
cephems.98 The first generation cephalosporins (e.g. cefazolin and cephalothin) were 
active predominantly against Gram-positive cocci.99,100 The second generation 
cephalosporins are more active against Gram-negative bacilli and are somewhat less 
effective against Gram-positive cocci.99 Unlike the first and second generation 
cephalosporins, the third generation cephalosporins have increased activity against 
both Gram-negative organisms.100–102 Among the fourth generation cephalosporins, 
cefepime is the most commonly used antibiotic. The fourth generation cephalosporins 
have the similar activity against Gram-positive bacteria as the first generation 
cephalosporins; however, they have a greater activity against Enterobacteriaceae and 
Pseudomonas aeruginosa than the third generation cephalosporins.103–105 The fifth 
generation cephalosporins (ceftaroline and ceftobiprole) notably have an improved 
activity against Gram-positive bacteria such as methicillin-resistant Staphylococcus 
aureus and vancomycin-intermediate Staphylococcus aureus strains.106,107 
2.2.1.3 Monobactams  
A currently marketed monobactam is aztreonam, an antibiotic with a very good activity 
against aerobic and fastidious Gram-negative bacilli such as Enterobacteriaceae and 
Pseudomonas aeruginosa strains.108,109 Aztreonam has poor activity against anaerobes 
and Gram-positive organisms.109 
2.2.1.4 Carbapenems 
Carbapenems are normally referred to as the antibiotics of last resort and are 
bactericidal for both Gram-negative and Gram-positive organisms.110 They are known to 
be the most effective antibiotics against many multidrug-resistant Gram-negative 
bacilli.111,112 Carbapenems include imipenem, ertapenem, meropenem and 
doripenem.110  
2.2.1.5 Beta-lactamase inhibitors 
Clavulanic acid, tazobactam and sulbactam are beta-lactamase inhibitors that inhibit a 
number of plasmid-mediated beta-lactamases. They generally do not inhibit 





inhibitors with beta-lactams significantly increases spectrum of activity against many 
organisms containing plasmid-mediated beta-lactamases.113,114   
2.2.2 Mechanism of action and resistance 
Beta-lactam antibiotics are bactericidal and inhibit the growth of sensitive bacteria by 
inhibiting the DD-transpetidases, the penicillin-binding proteins (PBPs) that facilitate 
the final step (transpeptidation) of peptidoglycan synthesis, an important component of 
the bacterial cell wall.115–117 Peptidoglycan, a murein, consists of amino acids and sugars 
that make up an important part of the bacterial cell wall.115 Beta-lactam antibiotics are 
analogues of D-alanyl-D-alanine, the terminal amino acid residues on the precursor N-
acetylmuramic acid/N-acetylglucosamine (NAM/NAG) peptide subunits of the 
peptidoglycan layer.115,117–119 This structural similarity allows the binding of beta-
lactams to the active site of PBPs.118,119  The beta-lactam ring irreversibly binds to the 
Ser403 residue of the PBP active site by acylation thereby preventing the final 
transpeptidation or crosslinking of nascent peptidoglycan layer by the PBPs, disrupting 
synthesis of the bacterial cell wall followed by cell death.119   
The main mechanisms of resistance to beta-lactam antibiotics are decreased 
penetration of beta-lactams due to the production of modified porins, loss of porins or a 
shift in the types of porins found in the outer membrane of Gram-negative bacteria, 
increased efflux from the cell through production of efflux pumps, or inactivation of 
beta-lactams by chromosome- and /or plasmid-encoded beta-lactamase enzymes 
(Figure 2). Among the above-mentioned, the most common mechanism of resistance is 
the production of beta-lactamases.120,121    
2.2.3 Beta-lactamases  
Increased use of beta-lactam antibiotics has been associated with the emergence of 
beta-lactamase-mediated bacterial resistance.123 Beta-lactamases are enzymes that 
inactivate beta-lactam antibiotics by cleaving the beta-lactam ring through an 
irreversible hydroxylation of an amide bond (Figure 3).89  
Two classification schemes for beta-lactamases are currently in use, the functional 
(Bush-Jacoby group) and molecular classification (Ambler classification).124,125 
Functional classification aligns beta-lactamases based on their ability to hydrolyze 





inhibitors.125 The widely used molecular classification (Ambler classification) is based 
on the amino acid sequences and divides the beta-lactamases into four classes.124 Class 
A, C, and D enzymes require serine at their active sites for substrate hydrolysis, whereas 
class B metallo-beta-lactamases utilize divalent zinc ion for substrate hydrolysis.125–127 
 
Figure 2. Diagram showing the mechanisms of beta-lactam resistance in Gram-negative bacilli.  
Hydrophilic channels formed by the porins in the outer membrane of a cell allow the uptake of beta-
lactams into the bacterium. In the periplasmic space, beta-lactam molecules bind irreversibly to the 
penicillin binding proteins (PBPs), leading to the inhibition of the peptidoglycan synthesis. (Taken from 
Nordmann et al. 2012).122 
    
The production of beta-lactamases may be inducible or constitutive.128 In Gram-positive 
bacteria, beta-lactamases are generally inducible, resulting in larger amounts of 
enzymes produced in the presence of an antibiotic.129 In Gram-negative bacteria, the 
production of beta-lactamases is frequently constitutive, i.e. the enzyme is produced 
even when the antibiotic is not present.129,130 However, ampicillin class C beta-
lactamases (AmpCs) are inducible in certain Gram-negative bacteria, such as Serratia, 






Figure 3. Diagram showing the mechanism of action of beta-lactamases.  
Beta-lactamase enzyme causes an opening in the beta-lactam ring rendering an active penicillin 
ineffective (inactive penicillin), courtesy of www.wiley.com.   
Resistance to beta-lactams emerged before the development of penicillin, the first 
discovered beta-lactam antibiotic. The first beta-lactamase was identified in E. coli in 
the early 1940s before the release of penicillin.69 After the introduction of penicillin, 
resistance to this antibiotic emerged in Staphylococcus aureus due to a plasmid-
mediated penicillinase that specifically hydrolyzed penicillin.68,69 Penicillinase spread 
quickly to other species of staphylococci.133 Resistance to penicillin led to the 
development of many new beta-lactams; however, with each new class of beta-lactams 
developed, new beta-lactamases active against that class of antibiotics emerged.86,134,135 
Some of these new classes of antibiotics were the third and fourth generation 
cephalosporins and carbapenems which became the most common agents for treating 
infections caused by Gram-negative bacilli.13,32,33,61,133 However, the rapid emergence of 
resistance to beta-lactams due to AmpCs, extended-spectrum beta-lactamases (ESBLs) 
and carbapenemases is of a great public health concern.13,41,45,88,129  AmpCs are beta-
lactamases that hydrolyze broad and extended-spectrum cephalosporins, but are not 
inhibited by beta-lactamase inhibitors.132 The following sections focused on the 
characteristics, epidemiology, and detection methods of the ESBL- and carbapenemase-
producing bacteria. 
2.2.3.1 Extended spectrum beta-lactamase-producing bacteria 
Extended spectrum beta-lactamases are beta-lactamase enzymes that have the ability to 





aztreonam, but not carbapenem or cephamycin antibiotics.136 ESBLs are reported 
worldwide among different bacterial species, including Enterobacteriaceae and non-
fermentative Gram-negative bacteria such as Pseudomonas and Acinetobacter species.137  
2.2.3.1.1 Class A extended-spectrum beta-lactamases 
CTX-M (cefotaximase, Munich), SHV (sulfhydryl variable) and TEM (Temoneira) types 
are the most clinically common Ambler class A ESBL enzymes, and are susceptible to 
beta-lactamase inhibitors (Table 1).61,129,136,137 The first plasmid-encoded ESBL enzymes 
were identified among Enterobacteriaceae in the 1980s;138 they were derived mainly 
from the narrow spectrum enzymes (TEM-1, TEM-2, or SHV-1) by point mutations 
resulting in amino acid changes conferring an extended-spectrum of activity against 
beta-lactams.139,140 Unlike SHV and TEM enzymes, CTX-M enzymes had an independent 
evolution.127 Although ESBLs were first reported as plasmid-encoded, they are not 
exclusively plasmid-encoded; recent studies have shown that ESBL genes are also 
carried on chromosomes.129,141 
- CTX-M-type ESBLs 
CTX-M enzymes were derived from the chromosomal cephalosporinase of Kluyvera 
species, and the first CTX-M enzyme was discovered in an E. coli clinical isolate from 
Munich, Germany in 1989.142 It was suggested that CTX-M genes were captured by 
mobile elements from the chromosomes of Kluyvera species.143–145  
CTX-M enzymes are classified into five groups; CTX-M-1, -2, -8, -9 and -25. Enzymes 
within the same CTX-M group share about 94% similarity, whereas ≤90% similarity is 
observed between members of different groups.146 CTX-M enzymes have greater 
hydrolytic activity against cefotaxime than other oxyimino-beta-lactams, hence the 
name CTX-M (cefotaximase, Munich).147,148 However, some CTX-M enzymes have 
greater activity against ceftazidime.149,150 CTX-M-15, -16, -19, -25, -27, and -32 have 
higher hydrolytic activity against ceftazidime due to point mutations around their active 
sites.149–156 In addition, CTX-M enzymes exhibit higher significant hydrolytic activities 
against cefepime than observed with other ESBL types.146 All CTX-M enzymes have 
ESBL phenotype, and are commonly identified among Enterobacteriaceae, mainly E. coli 





- TEM-type ESBLs 
The first TEM enzyme (TEM-1) was discovered in 1965 in Athens (Greece) from a 
patient infected with E. coli, named Temoneira, hence the name TEM.158 TEM-1 is the 
most common plasmid-mediated beta-lactamase causing ampicillin resistance among 
Enterobacteriaceae; responsible for up to 90% of ampicillin resistance in E. coli.129 Both 
TEM-1 and TEM-2 have hydrolytic activity against ampicillin and early-generation 
cephalosporins.139,140 All TEM-type ESBLs were derived from TEM-1 and TEM-2.159 
TEM-type ESBLs hydrolyze ceftazidime with higher efficiency than other oxyimino-
beta-lactams.160 Some TEM-type ESBL variants possess silent substitutions without 
amino acid changes (TEM-1a and TEM-1b) and others have single amino acid changes 
enough to assign a new number (TEM-3, -4, -5, etc.). To date, about 84 TEM variants 
have an ESBL phenotype. These are commonly identified in Enterobacteriaceae.161 
- SHV-type ESBLs 
SHV-type ESBLs are derived from narrow-spectrum SHV-1 or SHV-11 beta-lactamases 
as a result of point mutations.159 Initially, SHV-1 was described as plasmid-encoded and 
later as chromosomally encoded among K. pneumoniae isolates.162,163 SHV-1 or SHV-11 
is responsible for ampicillin resistance and accounts for up to 80% to 90% of resistance 
in K. pneumoniae.162–164 SHV-type ESBLs have greater hydrolytic activity against 
ceftazidime than other oxyimino-beta-lactams (cefotaxime, cefepime).165 SHV-type 
ESBLs are mainly found in Enterobacteriaceae and P. aeruginosa and the most common 
are SHV-2a, -5 and -12.166   
2.2.3.1.2 Class D extended-spectrum beta-lactamases 
OXA-type ESBLs are the only Ambler class D ESBL enzymes. OXA-type ESBLs are less 
common and were named OXA for their greater activity against oxacillin or cloxacillin 
and extended-spectrum beta-lactams.136 OXA-type ESBLs primarily hydrolyze 
ceftazidime and are poorly inhibited by clavulanic acid.127 About 16 OXA-type ESBL 
enzymes have been discovered; especially in Pseudomonas aeruginosa and E. coli 
strains.129,167  
2.2.3.2 Carbapenemase-producing bacteria  
Infections with ESBL-producing organisms has led to increased usage of carbapenems 





compromised by the emergence of carbapenemase-producing organisms.28,29 
Carbapenemases are beta-lactamases that hydrolyze almost all beta-lactam 
antibiotics.44,168 Depending on the type or class of carbapenemase, these enzymes 
hydrolyze penicillins, cephalosporins, monobactams and carbapenems.44 
Carbapenemases are most frequently produced by the Enterobacteriaceae and non-
fermenting bacteria such as Acinetobacter and Pseudomonas species.41,169 
Carbapenemases are classified into to Ambler classes A, B and D (Table 1).170  
2.2.3.2.1 Class A carbapenemases 
Class A enzymes can hydrolyze a wide variety of beta-lactams and are often poorly 
inhibited by the beta-lactamase inhibitors such as clavulanic acid or tazobactam.44 Class 
A carbapenemases include the NMC (not metalloenzyme carbapenemase), IMI 
(imipenem-hydrolysing beta-lactamase), SFC (Serratia fonticola carbapenemase), BIC, 
and SME (Serratia marcescens enzyme) enzymes which are chromosomally-encoded as 
well as KPC (Klebsiella pneumoniae carbapenemase), and GES (Guiana extended-
spectrum) carbapenemases which are mostly plasmid-encoded enzymes.44,171 Among 
these, KPC enzymes which were first identified in the USA,172 are the most clinically 
important and are now spread worldwide.45,173–177  
2.2.3.2.2 Class B carbapenemases 
Class B metallo-beta-lactamases (MBLs) are different from class A enzymes because 
they can hydrolyze all beta-lactams with the exception of aztreonam, and are resistant 
to beta-lactamase inhibitors.44,136 MBLs can be inhibited by metal ion chelators such as 
ethylenediaminetetraacetic acid (EDTA).44,136 These enzymes are mostly plasmid-
encoded or in some cases chromosomally-encoded and include the NDM (New Delhi 
metallo-beta-lactamase), VIM (Verona integron-encoded metallo-beta-lactamase), IMP 
(imipenemase), GIM (German imipenemase), SIM (Seoul imipenemase), DIM (Dutch 
imipenemase), SPM (Sao Paulo metallo-beta-lactamase), and AIM enzymes.44,169 The 
most clinically common MBLs are the VIM, IMP and NDM enzymes.44,45  
2.2.3.2.3 Class D carbapenemases 
Like class A carbapenemases, class D enzymes hydrolyze a wide range of beta-lactam 
antibiotics, and they are poorly inhibited by both beta-lactamase inhibitors and metal 





carbapenemases, OXA (oxacillinase), are divided into five subfamilies: OXA-23, OXA-
24/40, OXA-48, OXA-51 and OXA-58. The OXA-48-like carbapenemases are 
predominantly found in Enterobacteriaceae, and the OXA-23-like, OXA-24/40-like, OXA-
51-like and OXA-58-like in Acinetobacter species.44 OXA-48-like enzymes represent the 
main group of enzymes described worldwide.170 The enzymes belonging to the OXA-23, 
OXA-24/40, OXA-48 and OXA-58 subfamilies are mainly plasmid-encoded, whilst OXA-
51-like enzymes are chromosomally-encoded and intrinsic in Acinetobacter 
species.44,179      
2.3 Global epidemiology of ESBL- and carbapenemase-producing bacteria 
2.3.1 Epidemiology of ESBL-producers  
Enterobacteriaceae are the main bacterial species associated with the production of 
ESBLs.60 Enterobacteriaceae are commonly found in human gastrointestinal tract 
(GIT).180 However, these organisms can cause a variety of extra-intestinal infections in 
the lower and upper urinary tracts, bloodstreams, central nervous system, pelvis or 
abdomen and wounds.60 The most important Enterobacteriaceae species associated 
with ESBL production are E. coli and K. pneumoniae.61 ESBL-producing 
Enterobacteriaceae (ESBL-PE) often display resistance to multiple drugs and co-
resistance to other antibiotics used for treatment (aminoglycosides, fluoroquinolones 
and trimethoprim) is common.181 Treatment options for severely ill patients are limited, 
resulting in increasing morbidity and mortality rates.182 ESBL-PE species are therefore a 
growing public health concern worldwide. The prevalence and distribution of ESBLs 
varies widely in different geographical regions, differs from country to country, as well 













Defining characteristic(s) Representative enzyme(s) 
CA or TZB EDTA 
1 C Cephalosporins No No Greater hydrolysis of cephalosporins than 
benzylpenicillin; hydrolyzes cephamycins 
E. coli AmpC, P99, ACT-1, 
CMY-2, FOX-1, MIR-1 
1e C Cephalosporins No No Increased hydrolysis of ceftazidime and often other 
oxymino-beta-lactams 
GC1, CMY-37 
2a A Penicillins Yes No Greater hydrolysis of benzylpenicillin than 
cephalosporins 
PC1 
2b A Penicillins, early 
cephalosporins 
Yes No Similar hydrolysis of benzylpenicillin and 
cephalosporins 
TEM-1, TEM-2, SHV-1 
2be A Extended-spectrum 
cephalosporins, 
monobactams 
Yes No Increased hydrolysis of oxyimino-beta-lactams 
(cefotaxime, ceftazidime, ceftriaxone, cefepime, 
aztreonam) 
TEM-3, SHV-2, CTX-M-15, 
PER-1, VEB-1 
2br A Penicillins No No Resistance to clavulanic acid, sulbactam and 
tazobactam 
TEM-30, SHV-10 
2ber A Extended-spectrum 
cephalosporins, 
monobactams 
No No Increased hydrolysis of oxyimino-beta-lactams 
combined with resistance to clavulanic acid, 
sulbactam and tazobactam 
TEM-50 
2c A Carbenicillin Yes No Increased hydrolysis to carbenicillin PSE-1, CARB-3 
2ce A Carbenicillin, cefepime Yes No Increased hydrolysis of carbenicillin, cefepime, and 
cefprirone 
RTG-4 













Defining characteristic(s) Representative enzyme(s) 
CA or TZB EDTA 
2de D Extended-spectrum 
cephalosporins 
Variable No Hydrolyzes cloxacillin or oxacillin and oxyimino-beta-
lactams 
OXA-11, OXA-15 
2df D Carbapenems Variable No Hydrolyzes cloxacillin or oxacillin and carbapenems OXA-23, OXA-48 
2e A Extended-spectrum 
cephalosporins 
Yes No Hydrolyzes cephalosporins. Inhibited by clavulanic 
acid but not aztreonam 
CepA 
2f A Carbapenems Variable No Increased hydrolysis of carbapenems, oxyimino-beta-
lactams, cephamycins 
KPC-2, IMI-1, SME-1 
3a B (B1) Carbapenems No Yes Broad-spectrum hydrolysis including carbapenems 
but not monobactams 
IMP-1, VIM-1, NDM-1 
3a B (B3) Carbapenems No Yes Broad-spectrum hydrolysis including carbapenems 
but not monobactams 
CAU-1, GOB-1, FEZ-1 
3b B (B2) Carbapenems No  Yes Preferential hydrolysis of carbapenems ChpA, Sfh-1 
The Bush and Jacoby group or functional classification takes into account the substrate and inhibitor profiles whereas the Ambler or molecular classification is by 
protein sequence, whereby the beta-lactamases are classified into four molecular classes (A,B, C and D) based on conserved and distinguishing amino acids motifs. 





2.3.1.1 Epidemiology of ESBL-producing bacteria in Asia, America, and Europe 
In Europe, the prevalence of ESBL-PE varies between countries.62 The prevalence is low 
in Scandinavian countries but is rapidly increasing.185,186 A surveillance study conducted 
in South Western Sweden during 2004 to 2008 reported a greater increase in the 
prevalence of CTX-M-producing E. coli isolates in hospitals (0.2% - 2.5%) than in the 
community (0.2% – 1.6%).186 In contrast, the prevalence of ESBL-PE is high in the 
Southern and Eastern parts of Europe.62 Seven (6.7%) of 105 healthy humans from 
Spain were carriers of ESBL-producing E. coli, and CTX-M-14 was the most dominant 
enzyme.187 A study in Portugal reported the ESBL faecal carriage rate of 2.7% (3/112) 
in healthy children.188 In another study conducted in Portugal, the faecal carriage of 
ESBL-producing E. coli in patients with UTI caused by these microorganisms was 68% 
(36/53), but the household members and the non-household relatives of these patients 
also had ESBL-producing E. coli in faecal samples, 27.4% (20/73) and 15.6% (5/32), 
respectively, whilst in healthy unrelated controls the faecal carriage rate was 7.4% 
(4/54).189 In Germany, ESBL-producers were recovered from animals, including dogs, 
cats and horse, and the authors also described an active transmission of such organisms 
between humans and animals.190  
In America, data on ESBL-PE organisms both in hospital and community settings are 
scarce. Besides, a recent survey from the USA including 26 hospitals from 20 states 
reported the prevalence of 6.4% (195/3049) of ESBL-producers among 
Enterobacteriaceae isolates.191 Furthermore, surveillance studies have reported high 
prevalence rates ranging from 45% to 51% in South America.184,192 
In Asia, a survey conducted in various hospitals in India reported the prevalence of 
ESBL-producing Gram-negative bacilli ranging from 19% to 60%.193 In addition, a cross-
sectional study conducted in rural community of Thailand also reported a very high 
ESBL-PE faecal carriage of 58.2% in 160 healthy adult individuals (mean age; 56.0 ± 9.8 
years).194 In the later study, 94.3% of the isolates were positive for CTX-M gene.194  In 
China, among 270 healthy adults, the faecal carriage rate of ESBL-producing E. coli was 
7%.195 Unlike in most parts of the world where CTX-M-15 is predominant, in South-East 





2.3.1.2 Epidemiology of ESBLs in Africa 
Two reviews on ESBL-producing Enterobacteriaceae in Africa have been recently 
published.63,64 The prevalence rates of ESBL-PE vary from hospital to hospital and from 
country to country.62 In North Africa, a survey conducted in three Egyptian university 
hospitals reported a very high prevalence of 80% among 160 K. pneumoniae strains 
isolated from blood cultures of hospitalized patients with nosocomial bloodstream 
infections.198 In addition, a study conducted in one neonatal ICU in an Egyptian hospital 
also found a very high proportion of 79% of ESBL-producing K. pneumoniae isolates.199 
In another study conducted in nine adult ICUs in Egypt, the authors reported that 76.7% 
of K. pneumoniae and E. coli isolates causing bloodstream infections (BSIs) were ESBL-
producers.200 The ESBLs in the three mentioned Egyptian studies were not well 
characterized.198–200 The prevalence of ESBLs was also high in Tunisian children 
hospital, reaching up to 68% among E. coli isolates; with CTX-M-15 detected in 97% of 
such isolates.201 The proportion rates of 16%,202 and 31%,203 of ESBLs among 
Enterobacteriaceae have been recorded in Libyan and Algerian hospitals, respectively. 
Studies in North Africa showed the dominance of CTX-M enzymes, particularly CTX-M-
15.63,201–206 Furthermore, there are limited reports of SHV-type ESBLs,63 and TEM-type 
ESBLs are very scarce.63,201  
There are no enough data on the prevalence of ESBL-PE in Eastern Africa,63 as well as 
data on the characterization of ESBL genes.207,208 The hospital prevalence rates of 37%, 
38%, and 63% have been recorded in Kenya,209 Rwanda,208 and Ethiopia,207 
respectively. As in North Africa, CTX-M enzymes are the most common ESBLs 
circulating in Kenyan and Tanzanian hospitals.209,210 Although there are limited data on 
ESBL-PE in hospital settings from several West African countries, the dissemination of 
CTX-M enzymes is common in Niger, Nigeria and Cameroon.53,211–215 The prevalence 
ranges from 10% in Nigeria,215 to 83% in Cameroon.212  
In Malawi, only 0.7% of 1191 Enterobacteriaceae from blood cultures were ESBL-
producers.216 During the study period, ceftriaxone was the only available cephalosporin 
in Malawi and its use was highly restricted. The predominant ESBLs isolated were SHV-
12 (30%) and TEM-63 (20%).216 Besides Malawi, data on ESBL-producing organisms in 
Southern Africa are mainly from South Africa.63 A survey conducted in 59 South African 





between 2004 and 2009 reported a prevalence of 9% of ESBL-producers among 1218 
Enterobacteriaceae strains isolated from complicated intra-abdominal infections.217 
Another study conducted in several private and state hospitals (during 2008 -2009) in 
Cape Town metropolitan area reported a very low prevalence of ESBL-producing E. coli 
isolates of less than 7%.218 In the latter study, the most common ESBLs detected were 
CTX-M-15 (59.1%) and CTX-M-14 (31.8%).218 Different types of ESBL enzymes have 
been identified in many other Enterobacteriaceae species in South Africa.219–222 Based 
on previously published data, ESBL-producing Salmonella species had been a significant 
public health problem in South Africa, particularly in children whom extended-
spectrum cephalosporins were the preferred treatment. SHV and TEM enzymes, 
including ESBLs were the main enzymes described in such isolates.223–225  
In the community setting, the prevalence of ESBL-producing Enterobacteriaceae 
carriage in healthy humans in Africa is poorly studied.226 However, where studies have 
been done, the community carriage rates of ESBL-PE in Africa were high, ranging from 
7% in Cameroon,227 to 31% in Niger.53  
In children, a cross-sectional study conducted in Senegal reported a high ESBL carriage 
rate of 10% in 20 healthy children (mean age, 6.9 years) living in a remote village with 
no history of hospitalization or antibiotic usage. CTX-M-15 was the only ESBL enzyme 
identified among ESBL-positive E. coli isolates.49 The following studies have reflected 
the likely faecal carriage of ESBL-PE in the community settings among 
children.20,53,227,228  A prospective study in Niger reported an ESBL carriage rate of 31% 
within 24 hours of hospital admission in 55 children of less than five years of age.53 In 
the latter study, cross-transmission of ESBL-positive bacteria due to suboptimal hygiene 
was observed. In addition, CTX-M-15 enzyme was identified in 91% (20/22) of the 
isolates tested (13 E. coli, four E. cloacae, two K. pneumoniae and one E. asburiae), and 
SHV-2a and SHV-12 enzymes were found in one K. pneumoniae each.53 Furthermore, a 
cohort study conducted in Madagascar identified ESBL carriage of 21.2% within 48 
hours of hospital admission in 244 children (mean age, 38.3 months). The most 
common ESBL-PE isolates were K. pneumoniae (37%) and E. coli (36.9%); however, the 
ESBL enzymes were not characterized.228 In the latter study from Madagascar, risk 
factors associated with ESBL-PE carriage were prior hospitalization and use of invasive 





In adults, an ESBL-PE carriage rate of 6.7% was reported in a cross-sectional study 
conducted in Cameroon among 150 healthy students (mean age, 25 years) attending a 
clinic for their annual medical examinations.227 CXT-M-15 enzyme was found in all 
ESBL-PE isolates (nine E. coli and one K. pneumoniae).227 In another cross-sectional 
study conducted in five Tunisian cities (Tunis, Sfax, El Kef, Gafsa and Kairouan), the 
authors reported CTX-M-1-producing E. coli carriage in 7.3% (11/150) of healthy 
individuals.229 CTX-M-1-producing E. coli isolates have also been identified in 12.6% of 
79 food samples of animal origin in different supermarkets and butcheries in 12 
Tunisian cities.230 In Madagascar, ESBL-PE carriage was reported in 10.1% of 484 
patients of all ages (median age, 28 years) attending a health care setting  for the first 
time.20 As in other studies, CTX-M-15 was commonly identified, 86.8% of ESBL-PE 
isolates, mainly in E. coli and K. pneumoniae isolates.20 Other ESBL-PE isolates identified 
were SHV-12-producing E. cloacae, CTX-M-3-producing E. coli, CTX-M-1-producing E. 
coli and SHV-2a-producing K. pneumoniae.20 In the latter study, the occupational status 
of the head of household and poverty were risk factors for ESBL-PE carriage.20  
There is still lack of data on the epidemiology of ESBL-producing bacteria in many of 
African countries. However, based on the data described above, CTX-M-15 is the most 
predominant enzyme found in ESBL-PE, especially E. coli and K. pneumoniae isolates, 
both in hospital and community settings. There is no enough evidence of community 
carriage of ESBL enzymes belonging to TEM-type in ESBL-PE isolates20,49,53,227 
Furthermore, most of the above-described studies did not report the data regarding risk 
factors for the acquisition of ESBL-producing bacteria in hospital and community 
settings.63,200,204,231 The occurrence, in Tunisia, of CTX-M-1-producing E. coli isolates in 
food samples and healthy pets is of great concern since such organisms can spread to 
humans through food chain or contact with pets.230,232,233It is likely that there could be 
the transmission of ESBL-producing organisms through food chain or contact with pets 
in many African countries where studies are lacking.  
2.3.2 Global Epidemiology of carbapenemase-producing bacteria 
Carbapenemase-producing organisms are a significant and a growing problem 
worldwide. Although the actual prevalence of carbapenemase-producers is unknown in 





2.3.2.1 Epidemiology of carbapenemase-producing bacteria in America, Asia, and 
Europe  
By far, the most frequent class A carbapenemases are KPC enzymes.13,45,175,234,235 The 
KPC enzyme was first identified from a K. pneumoniae isolate in North Carolina, USA in 
1996 and soon afterwards caused outbreak in New York.172,177 Since then, outbreaks 
caused by KPC-producing K. pneumoniae have been reported in different countries, 
including Israel in 2004 and Greece in 2007.236 In Latin America, KPC enzymes 
(particularly KPC-2) are endemic in Colombia, mostly among Enterobacteriaceae.237–239 
However, the identification of KPC-2 enzyme in non-fermenters (P. aeruginosa) was 
first reported in Colombia.240 Of great concern, in China, hospital sewage has been found 
to harbour KPC-positive E. cloacae and C. freundii, and community infections with KPC-2 
producing isolates have also been documented.241,242 The mortality associated with 
infections caused by KPC-producing organisms ranges from 25% to 69%.175,243–247  
Metallo-beta-lactamases (MBLs) include three globally dominant carbapenemase types, 
the IMP, VIM and NDM enzymes.13 Imipenemase-1 (IMP-1) was the first known MBL 
enzyme identified from P. aeruginosa clinical isolate in 1988 in Japan.248 IMP-producing 
organisms have been reported to be endemic in Japan, Taiwan, Australia and Eastern 
China.249–256 VIM-1 was first identified in a P. aeruginosa clinical isolate in 1997 in 
Italy.257 VIM-1-producing Enterobacteriaceae are now endemic in Greece.258,259 
However, the VIM-2 enzyme has a worldwide distribution, with endemic spread in 
Greece, Spain and Italy, where it is predominantly identified in P. aeruginosa isolates.45    
NDM-1 enzyme was first detected in K. pneumoniae in 2008 in Sweden from a patient 
who had been transferred from a New Delhi hospital, in India.260 Initially many NDM-1-
producing Enterobacteriaceae reported in other countries were also isolated in patients 
with healthcare contact or travel-related to India, Pakistan and Sri Lanka.261,262 
Nonetheless, reports of NDM-1-producers in individuals who had not travelled to South 
Asia are increasing.13,263–265 The carriage of NDM-producing organisms in South Asia 
(India and Pakistan) has been estimated to be 5% to 15% in hospital settings.34,266 NDM 
enzymes have now spread into non-Enterobacteriaceae such as Pseudomonas 
aeruginosa and Vibrio cholera, and have been identified in the sewage and tap water in 
India and Vietnam.262,267,268 NDM-1 has also been found in A. baumannii clinical isolates 





are also widespread in the USA.262 To date, there is no evidence that NDM-producers are 
more virulent than other strains, however, they present limited treatment options.272 In 
Greece, the mortality rates associated with MBLs range from 18% to 67%.13,273 
The most clinically predominant oxacillinases are the OXA-48-like carbapenemases 
commonly found in Enterobacteriaceae isolates.13,263–265 The first report of OXA-48 
enzyme was from Turkey in 2004 in a K. pneumoniae clinical isolate.274 Since then, OXA-
48-producing Enterobacteriaceae have been increasingly reported as a source of 
outbreaks in Turkey.275–278 However, there are increasing reports of OXA-48-producing 
organisms in countries such as France, the Netherland, Germany, Switzerland, Spain and 
the UK, especially through transfer of patients from areas where the OXA-48 enzyme is 
endemic.4,279–283 The mortality rates associated with OXA-producing organisms are still 
unknown.170     
2.3.2.2 Epidemiology of carbapenemase-producing bacteria in Africa 
A detailed systematic review on the epidemiology of carbapenemase-producing bacteria 
in Africa has been recently published by our group, in 2014.41 In Africa, the reports of 
carbapenemase-producing organisms in hospital setting are increasing; however, 
reports of such organisms in the community setting are very scarce.284–286 Figures 4 and 
5 show the spread of carbapenemase-producing bacteria in Africa. 
Class A carbapenemases 
There are still few reported cases of class A carbapenemases in Africa.55,287,288 KPC-2- 
positive K. pneumoniae and E. cloacae have been recovered from adult patients in South 
Africa. Prolonged hospital stay, multiple antibiotic treatments, use of invasive devices, 
and immunosuppression were associated with the acquisition of KPC-2-producers.55 
The first identification of KPC enzyme in non-Enterobacteriaceae isolate (P. aeruginosa) 
was recently reported in Tanzania.287  
Class B carbapenemases 
In Africa, VIM enzymes are by far the most reported MBLs.41 In North Africa, VIM-1,-19, 
-4 and -29 enzymes seem to be the common VIM enzymes identified in 
Enterobacteriaceae.284,289–294 So far, only one study from Tunisia has reported VIM-2 
positive Enterobacteriaceae (E. coli isolates).289 VIM-2-producing P. aeruginosa isolates 





d’Ivoire.297 Since its first identification in Africa,298 NDM-1 is increasingly reported in 
both Enterobacteriaceae and A. baumannii.299–304 Of more concern, there are several 
reports of NDM-producing bacteria identified in patients with no obvious link to South 
Asia.290,300,301,298  
Class D carbapenemases 
OXA-48 in Enterobacteriaceae and OXA-23 in Acinetobacter species are the most 
prevalent carbapenemases reported in Africa, particularly in North African countries41. 
OXA-48-producing Enterobacteriaceae are thought to be endemic in North African 
countries.305 Of note, the identification of OXA-48-producing Serratia marcescens in 
environmental water samples in Morocco increases the risk that such organisms can 
spread through contaminated water and poor sanitation.286 
 









Figure 5. Geographical distribution of carbapenemase-producing non-Enterobacteriaceae in Africa. 
2.4 Detection methods for ESBL- and carbapenemase-producers  
2.4.1 Detection of extended-spectrum beta-lactamases 
Extended-spectrum beta-lactamases can be detected with phenotypic or genotypic 
approaches.  
2.4.3.1 Phenotypic tests 
The phenotypic detection of ESBLs includes screening and confirmatory steps.137 
Screening involves testing for reduced susceptibility to extended spectrum beta-
lactams, including cefotaxime, ceftazidime, cefpodoxime, ceftriaxone or aztreonam.306 
Cefpodoxime is the most sensitive indicator for detecting ESBLs, because it can be 
hydrolyzed by all common CTX-M, SHV, and TEM ESBLs;307 however, it is less specific 
than the combination of cefotaxime (or ceftriaxone) and ceftazidime.306 
Confirmatory phenotypic tests are based on the demonstration of synergy between the 
extended spectrum beta-lactams and beta-lactamase inhibitors particularly clavulanic 
acid.307 Several confirmatory tests including combination disc test, double-disc synergy 





automated systems (the Vitek ESBL and BD Phoenix ESBL tests) that use the above-
mentioned detection principle are in use in many clinical microbiology laboratories.308–
312  
2.4.3.1.1 Combination disc test (CDT) 
The CDT detects the production of ESBL enzymes based on the principle that they 
hydrolyze cephalosporin antibiotics and are inhibited by clavulanic acid (Figure 
6).306,307 Cefepime alone and in combination with clavulanic acid is preferred in isolates 
with inducible AmpC enzymes as this antibiotic is stable to AmpC beta-lactamases.313 
AmpC enzymes interfere with clavulanic acid synergy and detecting ESBL production in 
such isolates using cefotaxime or ceftazidime is challenging.314,315 The test is cheap and 
easy to perform, and interpretation is straightforward. The sensitivity and specificity of 
this test using cefotaxime and ceftazidime alone and in combination with clavulanic acid 
have been reported to be 96% and 100%, respectively;316 however, the sensitivity of 
this test can be further increased by using cefepime alone and in combination with 
clavulanic acid.313   
 
 
Figure 6. Combination disc test (CDT) showing an increase by at least 5mm for cefotaxime-clavulanic 
acid, ceftazidime-clavulanic acid and cefepime-clavulanic acid as compared to cefotaxime, ceftazidime and 
cefepime, respectively. CPM, Cefepime; CPM+CV, Cefepime-clavulanic acid; CAZ, Ceftazidime; CAZ+CV, 





2.4.3.1.2 Double-disc synergy test (DDST) 
The DDST was the first test designed to detect ESBL production in 
Enterobacteriaceae.317 The cephalosporin discs are applied to a plate next to a disc 
containing clavulanate (amoxicillin-clavulanate).318 A positive result is indicated when 
the zone of inhibition around any of the cephalosporin discs is augmented in the 
direction of the disc containing clavulanate.306 This method has remained a reliable test 
for the detection of ESBLs in clinical microbiology laboratories.306 In addition, the DDST 
is also cheap and easy to perform, however, reading the results is sometime difficult.307 
2.4.3.1.3 ESBL E-tests 
The ESBL E-tests contain the gradients of cephalosporin alone at one end of the strip 
and combined with 4 µg/ml of clavulanic acid on the other end. The ESBL E-test is 
considered positive when the minimum inhibitory concentration (MIC) of the 
cephalosporin combined with clavulanic acid is reduced by ≥8-fold as compared with 
the MIC of the cephalosporin alone or if a deformed ellipse or phantom zone is present. 
The ESBL E-test is easy to perform but the interpretation of results is sometimes 
challenging.306,312 In 2002, a study conducted in The Netherlands reported failure of 
laboratory technicians to recognize the phantom zones or ellipse deformation in 30% of 
cases.312 
2.4.3.1.4 ESBL Nordmann Dortet Poirel (ESBL NDP) test 
This is a newly developed phenotypic test for the detection of ESBLs in 
Enterobacteriaceae.319 The ESBL NDP test detects the production of ESBL based on the 
hydrolysis of cefotaxime. A red phenol solution is used as a pH indicator, and when a 
protein extract from the bacterium is mixed with red phenol solution containing 
cefotaxime, ESBLs contained within the protein extract hydrolyze the antibiotic, thus 
forming an acidic solution which causes the pH indicator to turn from red to yellow or 
orange. In the presence of tazobactam the activity of ESBLs will be inhibited, and the pH 
indicator will remain red (unchanged colour), thus confirming the production of the 
ESBL (Figure 7).319 Its sensitivity and specificity in detecting CTX-M-type and SHV-12 
enzymes have been reported to be 98.0% and 99.8%, respectively.320  Only few studies 






Figure 7. The ESBL NDP test showing the hydrolysis of cefotaxime in CTX-M-15-producing K. pneumoniae 
isolate (tube B). The action of ESBL enzyme (CTX-M-15) is inhibited in the presence of tazobactam (tube 
C). There is no hydrolysis of cefotaxime in case of ESBL negative E. coli (tube B).  
2.4.3.2 Genotypic tests 
Polymerase chain reaction (PCR) and subsequent sequencing of ESBL genes or DNA 
microarray-based methods are used for genotypic confirmation of the presence of 
specific ESBL genes. 61,306 Singleplex or multiplex PCR techniques may be used.321 
Molecular tests remain the gold standard and are technically challenging, however, they 
have the advantage of identifying the specific type of ESBL gene present in a 
bacterium.2,322 These techniques can detect low-levels of resistance, and can be 
performed without prior culture of the microbiological specimens.2 The PCR tests are 
rapid and the results are usually obtained within six hours with excellent sensitivity and 
specificity.323 The main disadvantages of molecular techniques are their cost and 
inability to detect unidentified novel ESBL genes.323  
2.4.2 Detection of carbapenemases 
Rapid detection of carbapenemases is crucial to guide appropriate antibiotic therapy 
and containment strategies.323 However, it remains difficult to detect carbapenemase-
producing organisms due to the lack of a universal screening medium that is able to 
detect all types of carbapenemases.324 A novel screening medium (SUPERCARBA 
medium) shows promise in this regard, but requires further evaluation.50,325–327 Most 
microbiology laboratories rely on routine antibiotic susceptibility test results obtained 





producing organisms.295,296,328–331 These methods are sometimes unable to detect 
carbapenemase producers which may show intermediate resistance or susceptibility to 
carbapenems on routine screening.13 MALDI-TOF and ultraviolet spectrophotometer 
are the emerging techniques which allow the detection of carbapenemase within few 
hours.306,332–335 Notably, automated systems have been shown to be unreliable in 
detecting all types of carbapenemase enzymes.336 Phenotypic tests that are currently 
used for confirming the production of carbapenemases, include the modified hodge test, 
carbapenemase inhibitor methods and the Carba NP test.323,330,337,338  
2.4.2.1 Phenotypic tests 
A number of phenotypic tests, most of which are the disc diffusion, have been described 
and evaluated for detection of carbapenemase-producing organisms.338   
2.4.2.1.1 The modified Hodge test (MHT) 
The clover leaf method or MHT is a recommended phenotypic test (by the clinical and 
laboratory standards institute) for detection of carbapenemase activity in vitro.339 The 
MHT is based on the inactivation of a carbapenem antibiotic by a carbapenemase-
producing strain that enables the growth of carbapenem-susceptible indicator strain to 
extend towards a carbapenem-containing disc, along the streak of inoculum of the 
tested strain, forming a cloverleaf-like shape or indentation (Figure 8). The MHT detects 
all types of carbapenemases without classifying the type of enzymes produced by the 
organisms.339 However, this test lacks both sensitivity and specificity .340 In addition, 
there are reports of false-positive results, involving  CTX-M-producing organisms with 
reduced outer membrane permeability which make the interpretation of the results 






Figure 8. The modified hodge test showing the production of carbapenemase in KPC-producing K. 
pneumoniae by the formation of cloverleaf-like shape or indentation between the test strain and an 
indicator strain, E. coli ATCC 25922 (Figure 8B). In carbapenemase negative strain, there is no formation 
of cloverleaf-like shape or indentation (Figure 8A). IPM: imipenem, ETP: ertapenem, MEM: meropenem. 
 
2.4.2.1.2 Carbapenemase inhibitor methods (synergy tests) 
These methods are based on the synergy between carbapenems and beta-lactamase 
inhibitors.342 For detecting MBLs producers, carbapenem disc alone and in combination 
with EDTA are used.343 This method uses the chelating agent, EDTA, to inhibit the 
hydrolysis of carbapenems.343 An increase, in zone diameter, by at least 5 mm for the 
carbapenem tested in combination with EDTA as compared to corresponding 
carbapenem tested alone is an indication of MBL production.306  
The detection of class A enzymes, particularly KPC, is based on using carbapenem disc 
alone and in combination with boronic acid.344 Boronic acid compounds inhibit the 
hydrolysis of carbapenems by KPC enzymes.344 They are serine-type beta-lactamase 
inhibitors that were originally used in detection of AmpCs in Enterobacteriaceae.344 The 
test is considered to be positive when there is an increase in the zone diameter of at 
least 4 mm for carbapenem plus boronic acid as compared to carbapenem alone.306 
2.4.2.1.3 The Carba NP test 
The Carba NP test is recommended by the European committee on antimicrobial 
susceptibility testing (EUCAST) as a confirmatory test for carbapenemase production.306 
The principle of the Carba NP test is the same as for the ESBL NDP test. The Carba NP 
test is based on the detection of imipenem hydrolysis (Figure 9).337 This test was 





species.337,345 The Carba NP test cannot determine the types of carbapenemase being 
detected.346 Different studies have reported the Carba NP test sensitivities ranging from 
80% -100%, with specificity of 100%.337,347–350 The Carba NP test appear to be easy-to-
use, rapid (results obtained within two hours) and cheap, but requires further 
evaluation.323 
 
Figure 9. The Carba NP test showing the hydrolysis of imipenem by KPC-producing K. pneumoniae.  
In the absence of carbapenemase enzyme, imipenem hydrolysis is not detected.   
2.4.2.2 Genotypic tests 
As with the detection of ESBLs, molecular tests remain the reference standard for 
detecting carbapenemase genes. PCR and subsequent sequencing or DNA microarray-
based tests are used.323 Commercially available DNA microarrays that are able to detect 
carbapenemase and ESBL genes have been evaluated in different settings 
worldwide.351–356 The principle of a DNA microarray is based on the fact that a 
complementary sequence of DNA will hybridize to immobilized DNA molecules.357 The 
immobilized single-stranded of known nucleotides sequence is used to detect and 
identify beta-lactamase genes. DNA microarrays have excellent sensitivity (100%) and 
specificity (100%)  in detecting different types of known carbapenemases but they are 






The data on the epidemiology of ESBL- and carbapenemase-producing bacteria in the 
African community setting remain scarce.  There are also few studies on the prevalence 
of ESBL- and carbapenemase-producers in healthy individuals in the community.49,229 
Furthermore, only few studies describing the acquisition of ESBL- and carbapenemase-
producing bacteria at birth have been conducted worldwide.358,359 Therefore, we sought 
to study the epidemiology of ESBL- and carbapenemase-producing bacteria in a birth-
cohort among apparently healthy South African children of less than one year of age and 





3. Material and Methods 
3.1 Study design 
This was a pilot study nested within an ongoing longitudinal prospective birth-cohort, 
the Drakenstein Child Health Study (DCHS). The DCHS was launched in 2011 and is 
enrolling 1000 mother-infant pairs.  
3.2 Study population and sampling   
The study was conducted in the Drakenstein sub-district, a peri-rural setting 60 
kilometres outside Cape Town, South Africa. This sub-district has a stable but low 
socioeconomic population status of about 200,000 persons.360 Pregnant women were 
enrolled at Paarl Hospital during their 20-24 week ultrasound scan visit and followed 
until childbirth. Infants were enrolled at birth and the mother-child pairs are being 
followed until the child is five years of age.361  
This pilot study was conducted on a subset of mother-infant pairs from whom stool 
samples were available at the time of this study. Stool samples were collected at 
delivery from both the mothers and infants and at two further specified intervals (5-12 
and 20-28 weeks) from the infants. In addition, data on potential relevant exposures 
were recorded. Variable included the maternal age, ethnicity, hospitalization in the 
previous two years, maternal HIV status, medication or supplement administration at 
birth, mode of delivery, infant gender, breastfeeding prior to discharge, admission to 
nursery and socioeconomic data. 
3.3 Collection, transportation, and storage of stool samples 
3.3.1 Maternal and infant faecal sample collection at the clinic 
Fifty microliter sterile, dry screw-top containers (Lasec, Cape Town, South Africa) were 
used for stool sample collection. The maternal stool samples were collected by the study 
or healthcare staff at birth. Stool passed in a bedpan was collected using the spoon 
attached to the lid of the stool collection container. For the infants, the meconium 
samples were collected by a registered nurse into the specimen container using a 
spatula. When no spontaneous passage of stool had occurred by the time a participant 
was being weighed, the meconium was aspirated from the rectum using a small soft 
plastic tube. The sample was aspirated into the tube or syringe and decanted into the 
specimen collection container. Stool samples were not collected if mixed with urine. The 





3.3.2 Infant stool collection at home 
The mothers were supplied with the stool collection containers, a specimen bag labelled 
with PID, spatula and gloves. The stool collection procedure was explained to the 
mothers and they were advised to collect a fresh stool sample and deliver to the study 
staff within four hours of collection. The mothers were also advised not to collect urine, 
soil, water (from the toilets), or other materials with the stool, as these may 
contaminate the actual samples. In addition, for infants, collecting samples from the 
diapers was discouraged; however, the mothers were allowed to place a plastic wrap 
between the baby’s bottom and a diaper (or to put a diaper on inside out). The stool 
samples were transported in ice box from the study site to the Division of Medical 
Microbiology laboratory at the University of Cape Town (South Africa) and stored at -
80°C without thawing until processing. 
3.4 Screening of ESBL- and carbapenemase-producing Gram-negative 
bacilli 
3.4.1 Inoculation of stool samples 
Figure 10 summarizes the laboratory procedures performed in this study. The stool 
samples were screened for the presence of ESBL- and carbapenemase-producing Gram-
negative bacilli. Each stool sample was suspended into 100 µl of 1% phosphate-buffered 
saline (PBS) (containing 137 mM NaCl, 2.7 mM KCL, 10 mM NaHPO4, 1.8 mM KH2PO4, 
and distilled water (pH 7.4)) and vortexed until it was clearly suspended. Stool samples 
were suspended in PBS because it is isotonic and non-toxic to bacterial cells with 
osmolarity and ion concentrations of solution matching those in human body.362 Forty 
microliters of stool suspension was inoculated onto ChromID ESBL agar and ChromID 
CARBA agar (bioMérieux, Marcy I’Etoile, France); for the detection of presumptive 
ESBL- and carbapenemase-producing bacteria, respectively. ChromID ESBL agar is a 
chromogenic medium capable of detecting presumptive ESBL-producing as well as the 
majority of carbapenemase-producing Gram-negative bacilli.363 It contains a mixture of 
antibiotics, including cefpodoxime which is a selective antibiotic used for screening for 
ESBL production.363,364 ChromID CARBA agar contains specific antibiotics that select for 
the growth of presumptive carbapenemase-producing Gram-negatives. Both the 






During each experiment, positive and negative controls were used. Thus, for ChromID 
ESBL medium, Escherichia coli American type culture collection (ATCC) 25922 (negative 
control) and Klebsiella pneumoniae ATCC 700603 (positive control) strains were used. 
E. coli ATCC 25922 does not produce any of the ESBL or carbapenemase enzymes, 
whilst K. pneumoniae ATCC 700603 produces an ESBL enzyme (SHV-18). The ATCC 
strains were commercially supplied by Davies Diagnostic (Randburg, Johannesburg, 
South Africa). For ChromID CARBA medium, E. coli ATCC 25922 (carbapenemase-
negative) and confirmed KPC-, NDM-, and OXA-48-producing K. pneumoniae clinical 
isolates (carbapenemase-producers) were included as quality controls in each run.  
The inoculated plates were incubated aerobically at 37°C. The bacterial growth was 
checked after 24 and 48 hours of incubation as per manufacturer’s instructions. 
According to the manufacturer’s specifications, pink to burgundy colonies should be 
identified as E. coli isolates, whereas green or blue colonies should be identified as 
Klebsiella, Enterobacter, Serratia, and Citrobacter species. Proteus, Morganella, and 
Providencia species would appear as dark brown or light brown colonies (bioMérieux, 
Marcy I’Etoile, France).  
3.4.2 Isolation of Gram-negative bacilli 
Presumptive ESBL and carbapenemase producers that grew on ChromID ESBL agar and 
ChromID CARBA agar were subcultured onto MacConkey agar plates (National Health 
Laboratory Services, Greenpoint, Cape Town, South Africa), which select for Gram-
negative bacteria, and differentiate them as lactose or non-lactose fermenters. The 
plates were aerobically incubated at 37°C for 24 hours, and after overnight incubation, 
the organisms were Gram-stained to confirm the Gram-negative bacilli.365  
Pure Gram-negative isolates were preserved in skim-milk tryptone glucose glycerol 













Figure 10. Summary of laboratory procedures performed in this study.  
-, Negative; +, Positive; UV, Ultraviolet; PFGE, Pulsed-field gel electrophoresis. 
3.5 Identification and antibiotic susceptibility testing 
The isolated Gram-negative bacilli were tested with the Vitek 2 system (bioMérieux, 
Marcy I’Etoile, France) for identification and antibiotic susceptibility testing (AST). Vitek 
2 system is an automated system that identifies the bacterial strains and their antibiotic 
susceptibility profiles (bioMérieux, Marcy I’Etoile, France). The Gram-negative card was 
used, which is able to identify 135 taxa of the most clinically and significant fermenting 





containing up to 20 antibiotics, each present over a range of concentrations. The system 
allows kinetic analysis by reading the turbidity of the growth of the tested isolate in the 
presence of antibiotics to perform linear regression analysis and ultimately determine 
algorithm-derived minimum inhibitory concentrations (MICs) (bioMérieux, Marcy 
I’Etoile, France). 
Depending on the bacterial strain tested, the MICs for antibiotics shown in Table 2 were 
determined. Therefore, based on Vitek 2 system results, the isolates were defined as 
being resistant, intermediate or susceptible to the tested antibiotics according to the 
criteria recommended by the Clinical and Laboratory Standards Institute (CLSI).339   
Table 2. Names and classes of antibiotics tested 
Class of antibiotic(s) Antibiotic(s) tested 
1. Penicillins  Ampicillin 
2. Penicillins + beta-lactamase inhibitors  Amoxicillin + clavulanic acid 
3. Antipseudomonal penicillins + beta-lactamase inhibitors  Piperacillin-tazobactam 
4. Non-extended spectrum cephalosporins  Cefuroxime 
 Cefuroxime Axetil 
5. Cephamycin  Cefoxitin 
6. Extended spectrum cephalosporins  Cefotaxime 
 Ceftazidime 
 Cefepime 
7. Carbapenems  Ertapenem 
 Imipenem 
 Meropenem 
8. Aminoglycosides  Gentamicin 
 Amikacin 
9. Fluoroquinolones  Ciprofloxacin 
10. Glycylcyclines  Tigecycline 
11. Polymyxins  Colistin 
12. Nitrofurans  Nitrofurantoin 






3.6 Phenotypic tests for confirmation of suspected ESBL- and 
carbapenemase-producing bacteria 
3.6.1 Confirmatory test for ESBLs 
The combination disc test (CDT) was used to confirm the production of extended-
spectrum beta-lactamase. Stored bacterial isolates were removed from -80°C and 
allowed to thaw at room temperature before subculturing. The isolates were 
subcultured on MacConkey agar (National Health Laboratory Services, Greenpoint- 
Cape Town, South Africa) and incubated aerobically at 37°C for 24 hours. The bacterial 
cells were suspended in 0.9% saline at a turbidity equivalent to 0.5 McFarland standard.  
The discs containing cefotaxime (30 µg), ceftazidime (30 µg), or cefepime (30 µg) alone; 
and in combination with clavulanic acid (30/10 µg) (Davies Diagnostic, Randburg, 
Johannesburg, South Africa) were placed on Mueller-Hinton agar plate inoculated with a 
bacterial suspension and incubated overnight at 37°C. K. pneumoniae ATCC 700603 
strain (ESBL-producer), and E. coli ATCC 25922 strain (ESBL-negative), were used as 
positive and negative controls, respectively. The test isolates were considered positive 
for the production of ESBL if the zone of inhibition increased by at least 5 mm for any 
antibiotic tested in combination with clavulanic acid as compared to corresponding 
antibiotic tested alone. The test was performed as previously described and the results 
were interpreted as recommended by the EUCAST guideline.306  
3.6.2 Confirmatory tests for carbapenemase 
The modified Hodge test (MHT) was used to confirm the production of carbapenemase 
production in Gram-negative isolates which were thawed at room temperature prior to 
subculture. MHT is a phenotypic test that detects the production of carbapenemase 
enzymes. When an enzyme is produced by the test strain, it inactivates a carbapenem 
antibiotic in the medium. This inactivation allows the growth of a carbapenem-
susceptible strain towards a carbapenem-containing disc along the streaked line of the 
test strain forming a cloverleaf-like shape or indentation.339    
All isolates were subcultured on MacConkey agar (National Health Laboratory Services, 
Greenpoint, Cape Town, South Africa) overnight and incubated aerobically at 37°C for 
24 hours. The test was performed as previously described,339 with slight modifications. 
Briefly, the indicator organism, E. coli ATCC 25922, was suspended in 0.9% 





suspension was then diluted to 1:10 ratio, by adding 1 ml of the 0.5 McFarland to 9 ml of 
0.9% physiological saline. A lawn of the 1:10 dilution of an indicator strain (E. coli ATCC 
25922) was inoculated on Mueller-Hinton agar plate using a sterile swab and allowed to 
dry. Meropenem (10 μg), ertapenem (10 μg), and meropenem discs (10 μg) (Davies 
Diagnostic, Randburg, Johannesburg, South Africa) were placed on the swabbed MHA 
plate. The test organism was streaked in three straight lines from the centre of the MHA 
plate to the edges of the discs; this was done to give much sharper results than the 
normal layout. The normal layout inoculates the test organisms in straight lines out 
from the edge of one disc at the centre of the plate.339 The following controls were used 
in each run; carbapenemase-producing K. pneumoniae ATCC BAA 1705 (KPC producer) 
and carbapenem-susceptible K. pneumoniae ATCC BAA 1706 strains (Davies Diagnostic, 
Randburg, Johannesburg, South Africa). The MHT positive test was indicated by the 
formation of a cloverleaf-like indentation of the indicator strain along the streak of the 
tested strain within the disc diffusion zone of inhibition (Figure 8).  
3.7 Detection of ESBL and carbapenemase genes from bacterial isolates 
3.7.1 Total DNA extraction from pure cultures  
DNA extraction was performed on 24-hour cultures of Gram-negative isolates grown on 
MacConkey agar. The total bacterial DNA of presumptive ESBL and carbapenemase 
producers was extracted using the ZR Fungal/Bacterial DNA MiniPrepTM kit (Zymo 
Research Corp., Irvine, California, USA). Briefly, a loopful of bacterial cells was picked 
from a MacConkey agar plate and suspended in 750 µl of lysis solution in ZR bashing 
bead TM lysis tube. Bacterial cells were homogenized and mechanically lysed for 
5 minutes using the TissueLyser LT™ (Qiagen, FRITSCH GmbH, Idar-Oberstein, 
Germany). DNA was extracted following the manufacturer’s instructions and eluted in a 
total volume of 25 µl. Extracted DNA was stored at -80°C until further processing. 
3.7.2 Assessment of bacterial DNA quality 
The DNA concentration (ng/µl) and purity (absorbance ratio at 260/280) of extracted 
DNA were determined by the Biodrop DUO (Whitehead Scientific, Cape Town, South 
Africa), where pure DNA was defined as having a 260/280 absorbance ratio ranging 
between 1.7 and 2.0.366 The quality or integrity of the DNA was confirmed by visualizing 
approximately 100 ng of DNA on a 2% agarose gel (w/v) containing 0.25 μg/μl of 





was then diluted to a working DNA concentration of 100ng/µl, and stored at 4°C until 
further analysis.  
3.7.3 Amplification of ESBL and carbapenemase genes by singleplex polymerase 
chain reaction 
PCR primers used in this study were synthesized using ABI DNA synthesizer at the 
Department of Molecular and Cell Biology, University of Cape Town, South Africa. The 
primers and PCR thermal cycling conditions used for the amplification of selected ESBL 
genes are shown in Table 3, and those for the carbapenemase genes in Table 4. 
The PCR reaction mixture was prepared in a pre-PCR room. A reaction mixture in a final 
volume of 25µl consisted of nuclease-free water, 1X green GoTaq® Flexi buffer, 1.5 mM 
MgCl2, 0.5 U of GoTaq® G2 Flexi DNA polymerase (Anatech, Johannesburg, South 
Africa), 2.5mM dNTP mix (Thermo Scientific, Pierce, USA), 0.5 µM of each primer, and 
100ng DNA template. The above-described reaction components were used to amplify 
CTX-M and all carbapenemase genes (Table 4), whilst 2.0 mM MgCl2 was used when 
detecting SHV and TEM genes. Singleplex conventional PCR amplification of each gene 











Table 3. Primers and conditions for amplification of common ESBL genes 
Target Product size (bp) Primers Sequence (5'→3') Reference PCR cycles (X 30) Reference 
 blaCTX-M1 560 CTXM1F 
CTXM1R 
CGCTTTGCGATGTGCAG 
ACCGCGATATCGTTGGT   
367 
367 
94ᵒC (5 min) 94ᵒC (30̍ s) 56ᵒC (30 s) 
72ᵒC (45 s) 72ᵒC (5 min) 
368 






94ᵒC (5 min) 94ᵒC (30̍ s) 56ᵒC (30 s) 
72ᵒC (60 s) 72ᵒC (5 min) 
368 






94ᵒC (5 min) 94ᵒC (30̍ s) 58ᵒC (30 s) 













Table 4. Primers and conditions for amplification of common carbapenemase genes 









94ᵒC (5 min) 94ᵒC (30̍ s) 55ᵒC (30 s) 










94ᵒC (5 min) 94ᵒC (30̍ s) 55ᵒC (30 s) 










94ᵒC (5 min) 94ᵒC (30̍ s) 55ᵒC (30 s) 










94ᵒC (5 min) 94ᵒC (30̍ s) 55ᵒC (30 s) 










94ᵒC (5 min) 94ᵒC (30̍ s) 55ᵒC (30 s) 










94ᵒC (5 min) 94ᵒC (30̍ s) 62ᵒC (30 s) 
72ᵒC (50 s) 72ᵒC (5 min) 
368 






94ᵒC (5 min) 94ᵒC (30̍ s) 62ᵒC (30 s) 






3.8 Gel electrophoresis and visualization of the amplicons  
Ten microliter of PCR products (amplicons) were analyzed on a 2.0% (w/v) agarose gel 
containing 0.25 µg/ml of ethidium bromide, run in 1X TAE buffer (40 mM Tris, 20 mM 
acetic acid, 1 mM EDTA, pH 8.0) at 100 volts for 1 hour. A 100 bp molecular weight 
ladder (Thermo Scientific, Pierce, USA) was used as a maker to estimate the size of the 
amplified fragments in each run. Amplicons were visualized by trans-illuminator, 
photographed by a digital camera, and transferred to computer data for labelling and 
storage. The specificity of amplified fragments was then confirmed by DNA sequencing. 
3.9 DNA sequencing and analysis of the amplicons 
 The PCR products were purified using the Zymo research sequencing clean-up kit 
(Zymo Research Corp., Irvine, California, USA), according to the manufacturer’s 
instruction. The PCR products were sequenced on both strands by using the primers 
shown in Table 3 for ESBL genes and Table 4 for carbapenemase genes. The purified 
DNA amplicons were sequenced by Inqaba Biotech (Inqaba Biotech, Pretoria, South 
Africa) using the ABI Prism BigDye® Terminator (Version 3.1) sequencing kit on ABI 
Prism 3500XL DNA Analyzer. The nucleotide sequences obtained were assembled using 
DNA Baser sequence assembler version 4.16.0 (2014, Heracle BioSoft, 
www.DnaBaser.com). Sequence alignment and analysis were performed online using 
the basic local alignment search tool (BLAST) available at the national center for 
biotechnology information (NCBI) (www.ncbi.nil.gov). Similar nucleotide alignment 
sequences of beta-lactamase genes were searched from the NCBI database.  The 
criteria for the positive hits were the query coverage of ≥ 90% of the reference 
alignment used and the sequence identity of ≥ 99%. 
3.10 Investigation of the relatedness of Klebsiella pneumoniae and 
Enterobacter cloacae isolates by pulsed-field gel electrophoresis 
3.10.1 Preparation of bacterial cell suspension 
Pulsed-field gel electrophoresis (PFGE) was performed on Klebsiella pneumoniae or 
Enterobacter cloacae isolates using the procedures described in the PulseNet USA 
protocols with the following slight modifications.373 Klebsiella pneumoniae ATCC BAA 
1705 was included as an internal control in each run to assess the reproducibility and 
quality of gels. Each of the tested isolates was subcultured on MacConkey agar plate. A 





suspension buffer (100 mM Tris-HCL, 10 mM EDTA). The bacterial suspension 
concentration was adjusted to 1.0 absorbance (optical density) by measuring at 590 nm 
wavelength using a Biodrop DUO (Whitehead Scientific, Cape Town, South Africa).   
3.10.2 Preparation of plugs 
Four hundred microliters of adjusted cell suspension, 20 µl of proteinase K (20 mg/ml) 
and 5 µl of lysozyme (20 mg/ml) (Inqaba Biotech, Pretoria, South Africa) were 
combined with 400 µl of melted 1% PFGE plug agarose (w/v): 1% sodium dodecyl 
sulphate (SDS) (v/v) (Bio-Rad Laboratories, Hercules, USA). The mixture was mixed 
gently pipetting up and down a few times to prevent DNA shearing by over-pipetting. 
This mixture was then pipetted into the slots of the PFGE plug mold (Bio-Rad 
Laboratories, Hercules, USA) by using a pipet tip. The plugs were allowed to solidify at 
room temperature for about 15 minutes. Three plugs were prepared for each isolate. 
3.10.3 Lysis of cells in agarose plugs 
After solidification, only two plugs were gently removed from the PFGE mold; and each 
plug was placed separately in a sterile 2 ml epperndorf tube containing 1.8 ml of cell 
lysis EC buffer, 25 µl of proteinase K (20 mg/ml) and 50 µl of lysozyme (20 mg/ml). The 
cell lysis EC buffer contained 6.0 mM Tris-HCl, 1.0 M NaCl, 0.1 M EDTA, 0.5% Brij 35 and 
0.5% Sarkosyl (pH 7.5). The epperndorf tubes were incubated in the heating block at 
55°C overnight without agitation.  
3.10.4 Washing of agarose plugs after cell lysis 
Following overnight incubation, all the plugs for the same strain were removed from the 
cell lysis EC buffer and placed in 50 ml blue topped tube. Enough sterile water and TE 
buffer (10mM Tris: 1mM EDTA pH 8.0) were pre-heated in a 50ᵒC water bath. Five 
millilitres of pre-heated sterile water was added into each tube containing a set of plugs 
for the same strain and shook the tubes at 2500 rpm on the rolling shaker at room 
temperature for 15 minutes. After 15 minutes, the water was carefully decanted 
(making sure not to lose the plugs) before adding another 5 ml of sterile water. Each 






3.10.5 XbaI and SpeI restriction enzyme digestion of DNA in agarose plugs 
A prepared plug was cut in 2.0 X 2.0 mm section using a sterile scalpel blade and placed 
in a sterile 2 ml epperndorf tube. Each plug was digested using a restriction enzyme, 
XbaI, in a total volume of 200 µl containing 174 µl of nuclease-free water, 4 µl (40 U) 
XbaI, and 20 µl of 10X Tango buffer and 2 µl of bovine serum albumin (BSA) (Thermo 
Scientific, Pierce, USA). The plugs were then incubated in the heating block at 37°C for 3 
hours without agitation.  Similar conditions and reaction components were used when 
digesting DNA in another 2.0 X 2.0 mm section of the plug using the 4 µl (40 U) SpeI 
instead of XbaI µl (40 U) enzyme.   
3.10.6 Electrophoresis and visualization under UV light  
The digested DNA was electrophoresed in 1% of PFGE agarose (w/v) (Bio-Rad 
Laboratories, Hercules, USA) with a Gene Navigator™ System (Amersham Biosciences, 
Uppsala, Sweden) for 18 hours with a pulse time of 5-60s at 200 V. PFGE lambda DNA 
ladder (Bio-Rad Laboratories, Hercules, USA) was included in each gel run. Once the run 
was complete, the gel was removed from the tank and stained in 400ml 0.5X TBE plus 
40ul EtBr (10mg/ml) for 30 minutes, de-stained in water for one hour, changing the 
water every 30 minutes. The gel was visualized by trans-illuminator, photographed by 
digital camera and transferred to computer data for labelling and storage. Images were 
converted to TIFF format for computer analysis. PFGE data were analyzed using 
BioNumerics software 6.6 (Applied Maths, Sint-Martens-Latem, Belgium). The 
dendrograms were constructed with dice coefficient, represented by the unweighted 
pair-group method, 1.0% optimization and 1.0% tolerance for the band migration 
position. Isolates were considered to belong to the same cluster when sharing high 
levels of pattern similarity (80-100%) and indistinguishable when sharing ≥90% 
similarity.141 
3.11 Statistical analysis 
The risk factors were statistically analyzed using the environmental performance index 
(EPI) Info version 7 software (Center for Disease Control and Prevention, Atlanta, 
Georgia, USA) by univariate analysis.  A p-value of ≤ 0.05 was considered statistically 
significant. The MIC values were analyzed using the WHONET 5.6 software (World 





3.12 Ethical considerations 
This study was approved by the Faculty of Health Sciences (FHS) Human Research 
Ethics Committee (HREC) of the University of Cape Town, South Africa (HREC reference 
number: 738/2013). Informed consent was obtained from all participants before 
enrolment in the broader Drakenstein Child Health Study, for which approval by HREC 
has previously been given (HREC reference number: 401/2009).  
In accordance with the English,374 Canadian,375 and United Kingdom (UK) National 
Health Service (NHS) guidelines;376 patients who screened positive for colonization 
were not treated in the absence of infection as further antibiotic resistance could result 













4.1 Characteristics of the study population 
Table 5 summarizes the characteristics of the study population. Ninety mothers and 116 
infants (90 mother-infant pairs) were included in this study. The longitudinal stool 
sampling at different time-points is shown in Figure 11. 
The mean age of mothers was 26.4 ± 5.5 years. Forty-one (45.6%) mothers were from 
the Mbekweni area, and the remainder from the TC Newman area (Table 5). Fifty 
(55.4%) were mixed race and 40 (44.4%) black African. Six (6.7%) of the mothers had 
been hospitalized in the previous two years, and 19 (21.1%) were HIV positive. At 
delivery, only 38 (42.2%) mothers were given medications or supplements during 
hospital stay or at discharge.  
The majority of infants were born by normal vaginal delivery (92/116; 79.3%). 
Seventeen (14.7%) and five (4.3%) infants were delivered by emergency and elective 
caesarean sections, respectively. The remaining two infants were born through the 
vaginal vacuum (0.9%) and assisted vaginal breech delivery (0.9%), respectively. Sixty-
one of 116 (53%) infants were males. Only seven (6%) infants were immediately 
admitted to the nursery after birth, and 109 (94%) were roomed with their mothers. 
The mean birth weight was 3.0 ± 0.5 kilograms (kg). Thirty-four (29.3%) were given 
medications and only nine (7.8%) had supplements before discharge. Ninety-nine of the 

















Table 5. Characteristics of mothers and infants included in the 
study 
Clinical characteristics Participants (%) 
Mothers (n= 90)  
Location  
 Mbekweni 41 (45.6) 
 TC Newman 49 (54.4) 
Maternal age (years), Median [IQR] 25 [22.5 - 31]* 
Ethnicity  
 Black African 40 (44.4) 
 Mixed race 50 (55.4) 
Hospitalization (in previous two years) 6 (6.7) 
HIV positive mothers  19 (21.1) 
Medication or supplement at delivery 38 (42.2) 
Education   
 Primary school 8 (8.9) 
 High school level 76 (84.4) 
 Tertiary level 6 (6.7) 
Household members, Median [IQR] 5 [3 - 6.5]* 
Household adults over 18 years old, Median [IQR] 2 [2 - 4.5]* 
Household children under 18 years old, Median [IQR] 1 [0.5 - 1.5]* 
Members sharing room with the mother, Median [IQR] 2 [2.5 - 3.5]* 
  
Infants (n= 116)  
Male infant  61 (52.6) 
Mode of delivery  
 Vaginal delivery 94 (81.0) 
 Caesarean section 22 (19.0) 
Preterm (< 37 weeks) 6 (5.2) 
Low birth weight (< 2500g) 15 (12.9) 
Birth weight (kg), Median [IQR] 3 [2.7 - 3.3]* 
Place of admission immediately after birth  
 Nursery 7 (6.0) 
 Roomed with the mother 109 (94) 
Babies given medication before discharge 34 (29.3) 
Babies given supplements before discharge 9 (7.8) 
Breastfeeding initiated prior to discharge 99 (85.3) 






Figure 11. Longitudinal stool sampling in 90 mothers and 116 infants at different time-points.  
The red and green colours represent the longitudinal sampling of stool samples among the infants. 
4.2 Bacterial isolation and identification 
Of the 309 stool samples screened using selective media, resistant Gram-negative bacilli 
were isolated in 27 stool samples (8.7%) tested. Of these, six were infant stool samples 
collected at birth, eight at 5-12 weeks and seven at 20-28 weeks, and the remaining six 
were maternal stool samples collected at delivery. Among the 39 Gram-negative bacilli 
isolated in this study, seven were from six mothers, and 32 from 20 infants. Table 6 
shows the distribution of Gram-negative bacilli in stool samples from the mothers and 














Table 6. Distribution of Gram-negative bacilli in stool samples from the mothers 
and infants at different time-points 
Time-point(s) 









Delivery 5 1 0 0 
Birth 5 1 0 0 
5-12 weeks 5 2 1 0 
20-28 weeks 5 0 0 2 
Total isolates (39) 20 8 3 8 
Table 7 shows the distribution and frequency of isolated Gram-negative bacilli among 
the mothers and infants. Among 39 bacterial isolates, the most frequently isolated 
bacterial species was Acinetobacter baumannii (n= 10), followed by Klebsiella 
pneumoniae (n= 7), Escherichia coli (n= 5), Enterobacter cloacae (n= 5), and 
Stenotrophomonas maltophilia (n= 4). Thirty-two of 39 isolates (82.1%) were recovered 
from the ChromID ESBL medium; 30 isolates after 24 hours and two after 48 hours of 
incubation (Table 8). The remaining seven isolates were recovered from the ChromID 











Table 7. Distribution and frequency of Gram-negative bacilli 
among the mothers and infants 
Bacterial species Number of isolates Frequency (%) 
Mothers Infants 
Enterobacteriaceae    
Enterobacter cloacae 1 4 5 (12.8) 
Klebsiella pneumoniae 2 5 7 (18.0) 
Escherichia coli 2 3 5 (12.8) 
Non-fermenters    
Acinetobacter baumannii 1 9 10 (25.6) 
Acinetobacter ursingii 0 2 2 (5.1) 
Pseudomonas putida 0 2 2 (5.1) 
Pseudomonas luteola 0 1 1 (2.6) 
Stenotrophomonas maltophilia 0 4 4 (10.3) 
Ochrobactrum anthropi 0 2 2 (5.1) 
Cupriavidus pauculus 1 0 1 (2.6) 
Total 7 32 39 (100) 
 
 





Number of bacterial isolates 




24 hours ChromID ESBL 7 5 4 14 30 
ChromID CARBA 0 0 1 3 4 
48 hours ChromID ESBL 0 0 0 2 2 





4.3 Antibiograms of Gram-negative bacilli 
The minimum inhibitory concentrations (MICs) for 19 antibiotics were determined by 
the Vitek 2 system (bioMérieux, Marcy I’Etoile, France). The results were categorized 
using the breakpoints and interpretive criteria provided by the CLSI when available.339 
For tigecycline, the EUCAST clinical breakpoints were used.377  
4.3.1 Antibiograms of Enterobacteriaceae 
Table 9 shows the MIC values for Enterobacteriaceae. All the isolates (n= 17) were 
susceptible to carbapenems (imipenem, ertapenem and meropenem), colistin and 
amikacin (Figure 12). High susceptibility rates were also observed for ciprofloxacin 
(94.1%), Piperacillin-tazobactam (88.2%), Cefoxitin (70.6%) and cefepime (70.6%), 
(Table 10). In contrast, the susceptibility rate for nitrofurantoin (29.4%) was very low, 
and 100% of the isolates were resistant to trimethoprim-sulfamethoxazole, with a very 
high 50% minimum inhibitory concentration (MIC50) of 384 µg/mL. The 
Enterobacteriaceae isolates were highly resistant to ampicillin (94.1%) and cefotaxime 
(82.4%), (Table 10). Most of the Enterobacteriaceae isolates (88.2%, 15/17) were 
resistant to at least one antibiotic from three or more classes of antibiotics and were 
classified as multidrug-resistant (Table 11). The resistance profiles of 17 





Table 9. Minimum inhibitory concentrations for different antibiotics in Enterobacteriaceae isolates 
Isolate no. Participant Isolate 







































507393-2 Mother E. cloacae ≥  32 ≥ 32 8 ≥ 64 ≥ 64 8 8 ≥ 64 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≥ 16 ≤ 0.25 1 64 ≤ 0.5 ≤ 20 
507394-1 Infant E. cloacae ≥  32 ≥ 32 8 32 32 ≤ 4 8 ≥ 64 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≥ 16 ≤ 0.25 1 128 ≤ 0.5 ≤ 20 
506261-1 Infant E. cloacae ≥  32 ≥ 32 ≤ 4 16 16 ≥ 64 4 16 ≤ 1 ≤ 0.5 0,5 ≤ 0.25 16 ≤ 1 ≤ 0.25 1 32 ≤ 0.5 ≤ 20 
506430-1 Infant E. cloacae ≥  32 ≥ 32 ≤ 4 32 32 ≥ 64 4 16 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 16 ≤ 1 ≤ 0.25 1 32 ≤ 0.5 ≤ 20 
104650-3 Infant E. cloacae ≥  32 ≥ 32 ≤ 4 32 32 ≥ 64 4 16 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 16 ≤ 1 ≤ 0.25 1 64 ≤ 0.5 ≤ 20 
101870-1 Infant E. coli 4 ≤ 2 ≤ 4 4 4 ≤ 4 ≤ 1 ≤ 1 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 32 ≤ 0.5 ≤ 20 
507214-1 Mother E. coli ≥  32 8 ≤ 4 4 4 ≤ 4 ≤ 1 ≤ 1 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 ≤ 16 ≤ 0.5 ≥ 320 
502192-1 Mother E. coli ≥  32 4 ≤ 4 ≥ 64 ≥ 64 ≤ 4 4 ≤ 1 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 ≤ 16 ≤ 0.5 ≤ 20 
102461-4 Infant E. coli ≥  32 16 ≤ 4 ≥ 64 ≥ 64 32 ≥ 64 4 8 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 128 ≤ 0.5 ≥ 320 
307338-1 Infant E. coli ≥  32 16 ≤ 4 ≥ 64 ≥ 64 32 ≥ 64 4 16 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 128 ≤ 0.5 ≥ 320 
106906-3 Infant K. pneumoniae ≥  32 ≤ 2 ≤ 4 2 2 ≤ 4 ≤ 1 ≤ 1 ≤ 1 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 64 ≤ 0.5 ≤ 20 
509599-1 Infant K. pneumoniae ≥  32 4 8 ≥ 64 ≥ 64 ≤ 4 ≥ 64 16 2 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≥ 16 0,5 1 64 ≤ 0.5 ≥ 320 
502317-1 Mother K. pneumoniae ≥  32 ≥ 32 16 ≥ 64 ≥ 64 ≤ 4 ≥ 64 16 4 ≤ 0.5 ≤ 0.25 ≤ 0.25 4 ≥ 16 1 2 128 2 ≥ 320 
501940-1 Infant K. pneumoniae ≥  32 16 8 ≥ 64 ≥ 64 ≤ 4 ≥ 64 4 2 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≥ 16 2 ≤ 0.5 128 ≤ 0.5 ≥ 320 
506433-1 Mother K. pneumoniae ≥  32 8 ≤ 4 ≥ 64 ≥ 64 ≤ 4 ≥ 64 8 2 ≤ 0.5 ≤ 0.25 ≤ 0.25 ≤ 2 ≥ 16 1 1 64 ≤ 0.5 ≥ 320 
102461-2 Infant K. pneumoniae ≥  32 16 32 ≥ 64 ≥ 64 ≤ 4 ≥ 64 ≥ 64 16 ≤ 0.5 ≤ 0.25 ≤ 0.25 8 ≥ 16 ≤ 0.25 2 64 ≤ 0.5 ≥ 320 
303200-1 Infant K. pneumoniae ≥ 32 16 32 ≥ 64 ≥ 64 ≤ 4 ≥ 64 ≥ 64 16 ≤ 0.5 ≤ 0.25 ≤ 0.25 8 ≥ 16 ≤ 0.25 2 64 ≤ 0.5 ≥ 320 
No., Number; AMP, Ampicillin; AMC, Amoxicillin + clavulanic acid; TZP, Piperacillin-tazobactam; CXM, Cefuroxime; CXA, Cefuroxime Axetil; FOX, Cefoxitin; CTX, Cefotaxime; CAZ, Ceftazidime; FEP, Cefepime; ETP, Ertapenem; IPM, 












Number (%) of 
resistant 
isolates 
Number (%) of 
intermediate 
isolates 




MIC50 MIC90 MICs range 
Ampicillin ≤ 8 16 (94.1) 0.0 1 (5.9) 32 32 4 – 32 
Amoxicillin/Clavulanic acid ≤ 8 6 (35.3) 5 (29.4) 6 (35.3) 16 32 2 – 32 
Piperacillin/Tazobactam ≤ 16 0.0 2 (11.8) 15 (88.2) 4 32 4 – 32 
Cefuroxime ≤ 8 13 (76.5) 1 (5.9) 3 (17.6) 64 64 4 – 64 
Cefuroxime axetil ≤ 4 13 (76.5) 1 (5.9) 3 (17.6) 64 64 4 – 64 
Cefoxitin ≤ 8 5 (29.4) 0.0 12 (70.6) 4 64 4 – 64 
Cefotaxime ≤ 1 14 (82.4) 0.0 3 (17.6) 8 64 1 – 64 
Ceftazidime ≤ 4 9 (52.9) 1 (5.9) 7 (41.2) 16 64 1 – 64 
Cefepime ≤ 2 3 (17.6) 2 (11.8) 12 (70.6) 1 16 1 – 16 
Ertapenem ≤ 0.5 0.0 0.0 17 (100) 0.5 0.5 0.5 – 0.5 
Imipenem ≤ 1 0.0 0.0 17 (100) 0.25 0.25 0.25 – 0.5 
Meropenem ≤ 1 0.0 0.0 17 (100) 0.25 0.25 0.25 – 0.25 
Amikacin ≤ 16 0.0 0.0 17 (100) 2 16 2 – 16 
Gentamicin ≤ 4 8 (47.1) 0.0 9 (52.9) 1 16 1 – 16 
Ciprofloxacin ≤ 1 0.0 1 (5.9) 16 (94.1) 0.25 1 0.25 – 2 
Tigecycline ≤ 1 3 (17.6) 0.0 14 (82.4) 1 2 0.25 – 2 
Nitrofurantoin ≤ 32 5 (29.4) 7 (41.2) 5 (29.4) 64 128 16 – 128 
Colistin ≤ 2 0.0 0.0 17 (100) 0.5 0.5 0.5 – 2 
Trimethoprim/Sulfamethoxazole ≤ 2 17 (100) 0.0 0.0 384 384 20 – 320 
MIC- Minimum inhibitory concentration, MIC50- Minimum inhibitory concentration required to inhibit the growth of 50% of organisms. MIC90- Minimum 







Figure 12. Susceptibility categorization of 17 Enterobacteriaceae isolates to 19 antibiotics by MICs 
determination.   
AMP, Ampicillin; AMC, Amoxicillin + clavulanic acid; TZP, Piperacillin-tazobactam; CXM, Cefuroxime; CXA, 
Cefuroxime Axetil; FOX, Cefoxitin; CTX, Cefotaxime; CAZ, Ceftazidime; FEP, Cefepime; ETP, Ertapenem; 
IPM, Imipenem; MEM, Meropenem; AMK, Amikacin; GEN, Gentamicin; CIP, Ciprofloxacin; TGC, 
Tigecycline; NIT, Nitrofurantoin; COL, Colistin; SXT, Trimethoprim-sulfamethoxazole. Findings were 







Table 11. Resistance profiles of 17 Enterobacteriaceae isolates to different antibiotics. 
Isolate No. Species Resistance profile 
No. of classes non-
susceptible/ No. of 
classes tested  
507393-2 E. cloacae AMP, AMC, CXM, CXA, CTX, CAZ, GEN, NIT, SXT 8/14 
507394-1 E. cloacae AMP, AMC, CXM, CXA, CTX, CAZ, GEN, NIT, SXT 8/14 
506261-1 E. cloacae AMP, AMC, CXM, CXA, FOX, CTX, CAZ, SXT 7/14 
506430-1 E. cloacae AMP, AMC, CXM, CXA, FOX, CTX, CAZ, SXT 7/14 
104650-3 E. cloacae  AMP, AMC, CXM, CXA, FOX, CTX, CAZ, NIT, SXT 8/14 
101870-1 E. coli SXT 1/14 
507214-1 E. coli AMP, SXT 2/14 
502192-1 E. coli AMP, CXM, CXA, CTX, SXT 5/14 
102461-4 E. coli AMP, AMC, CXM, CXA, FOX, CTX, FEP, NIT, SXT 9/14 
307338-1 E. coli  AMP, AMC, CXM, CXA, FOX, CTX, FEP, NIT, SXT 9/14 
106906-3 K. pneumoniae AMP, NIT, SXT 3/14 
509599-1 K. pneumoniae AMP, CXM, CXA, CTX, CAZ, GEN, NIT, SXT 7/14 
506433-1 K. pneumoniae AMP,  CXM, CXA, CTX, CAZ, GEN, NIT, SXT 7/14 
501940-1 K. pneumoniae AMP, AMC, CXM, CXA, CTX, GEN, CIP, NIT, SXT 9/14 
502317-1 K. pneumoniae AMP, AMC, CXM, CXA, CTX, CAZ, FEP, GEN , TGC, NIT, SXT 10/14 
102461-2 K. pneumoniae AMP, AMC, TZP, CXM, CXA, CTX, CAZ, FEP, GEN, TGC, NIT, SXT 10/14 
303200-1 K. pneumoniae AMP, AMC, TZP, CXM, CXA, CTX, CAZ, FEP, GEN,  TGC, NIT, SXT 10/14 
No., Number; AMP, Ampicillin; AMC, Amoxicillin-clavulanic acid; TZP, Piperacillin-tazobactam; CXM, Cefuroxime; CXA, 
Cefuroxime Axetil; FOX, Cefoxitin; CTX, Cefotaxime; CAZ, Ceftazidime; FEP, Cefepime; GEN, Gentamicin; CIP, 
Ciprofloxacin; TGC, Tigecycline; NIT, Nitrofurantoin; SXT, Trimethoprim-sulfamethoxazole. 
 
4.3.1 Antibiograms of non-fermenting Gram-negative bacilli 
The Vitek 2 system was able to determine the MICs for different antibiotics in 59.1% 
(13/22) of non-fermenters, mainly Acinetobacter baumannii (n= 10) and Pseudomonas 
species (n= 3) (Table 12). MICs for the remaining uncommon Gram-negative bacilli 
were not determined because the Vitek 2 system used was intended for use in clinical 
microbiology laboratory to identify and determine the susceptibility of clinically 





resistant to nitrofurantoin, trimethoprim-sulfamethoxazole, ampicillin, cefoxitin and 
cefuroxime axetil (Table 13). However, all isolates remained susceptible to colistin, 
ciprofloxacin, cefepime and amikacin. Two A. baumannii isolates were resistant to both 
imipenem and meropenem, and two P. putida isolates were resistant to both 
meropenem and tigecycline. Resistance profiles for different antibiotics in 13 non-





Table 12. Minimum inhibitory concentrations for different antibiotics in non-fermenting Gram-negative bacilli 
Isolate no. Participant Isolate 





































101277-1 Infant A. baumannii ≥ 32 4 - 32 32 ≥ 64 8 8 2 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 1 ≥ 512 ≤ 0.5 ≤ 20 
109201-1 Infant A. baumannii ≥ 32 4 - ≥ 64 ≥ 64 ≥ 64 32 16 8 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 ≥ 512 ≤ 0.5 ≤ 20 
102461-1 Infant A. baumannii ≥ 32 4 - ≥ 64 ≥ 64 ≥ 64 16 16 8 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 ≥ 512 ≤ 0.5 ≤ 20 
502307-2 Infant A. baumannii ≥ 32 ≥ 32 - - 16 ≥ 64 - 4 8 ≥ 16 ≥ 16 16 ≤ 1 ≤ 0.25 ≤ 0.5 ≥ 512 ≤ 0.5 ≤ 20 
104650-2 Infant A. baumannii ≥ 32 4 - - ≥ 64 ≥ 64 - 8 4 ≤ 0.25 0,5 ≤ 2 ≤ 1 0,5 ≤ 0.5 ≥ 512 ≤ 0.5 160 
106983-1 Infant A. baumannii ≥ 32 4 - - 32 ≥ 64 - 4 2 ≤ 0.25 ≤ 0.25 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 ≥ 512 ≤ 0.5 ≤ 20 
107029-2 Infant A. baumannii ≥ 32 4 - - ≥ 64 ≥ 64 - 8 4 ≤ 0.25 0,5 ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 ≥ 512 ≤ 0.5 ≤ 20 
104650-1 Infant A. baumannii ≥ 32 8 - - ≥ 64 ≥ 64 - 8 4 ≤ 0.25 0,5 ≤ 2 ≤ 1 0,5 ≤ 0.5 ≥ 512 ≤ 0.5 ≥ 320 
502307-1 Infant A. baumannii ≥ 32 ≥ 32 - - 16 ≥ 64 - 4 8 ≥ 16 ≥ 16 16 ≤ 1 <0.25 ≤ 0.5 ≥ 512 ≤ 0.5 ≤ 20 
507393-1 Mother A. baumannii 16 4 - - ≥ 64 ≥ 64 - 4 4 ≤ 0.25 0,5 ≤ 2 ≤ 1 0,5 ≤ 0.5 ≥ 512 ≤ 0.5 ≥ 320 
106906-4 Infant P. putida ≥ 32 ≥ 32 8 ≥ 64 ≥ 64 ≥ 64 16 4 2 1 4 ≤ 2 ≤ 1 ≤ 0.25 ≥ 8 256 ≤ 0.5 ≥ 320 
106906-2 Infant P. putida ≥ 32 ≥ 32 ≤ 4 ≥ 64 ≥ 64 ≥ 64 16 4 2 1 4 ≤ 2 ≤ 1 ≤ 0.25 ≥ 8 ≥ 512 1 ≥ 320 
107029-1 Infant P. luteola ≥ 32 16 ≤ 4 - ≥ 64 ≥ 64 - ≤ 1 ≤ 1 - - ≤ 2 ≤ 1 ≤ 0.25 ≤ 0.5 256 ≤ 0.5 ≤ 20 
No., Number; * ≤ 1 µg/mL breakpoint value for Pseudomonas species; AMP, Ampicillin; AMC, Amoxicillin + clavulanic acid; TZP, Piperacillin-tazobactam; CXM, Cefuroxime; CXA, Cefuroxime Axetil; FOX, Cefoxitin; CTX, Cefotaxime; 
CAZ, Ceftazidime; FEP, Cefepime; ETP, Ertapenem; IPM, Imipenem; MEM, Meropenem; GEN, Gentamicin; AMK, Amikacin; CIP, Ciprofloxacin; TGC, Tigecycline; COL, Colistin; NIT, Nitrofurantoin; SXT, Trimethoprim-





Table 13. Resistance profiles of 13 non-fermenting Gram-negative bacilli to different 
antibiotics. 
Isolate No. Species Resistance profile 
No. classes non-
susceptible/ No. classes 
tested 
507393-1 A. baumannii AMP, CXA, FOX, NIT, SXT  5/13 
107029-2 A. baumannii AMP, CXA, FOX, NIT, SXT  5/13 
106983-1 A. baumannii AMP, CXA, FOX, NIT, SXT  5/13 
104650-2 A. baumannii AMP, CXA, FOX, NIT, SXT  5/13 
104650-1 A. baumannii AMP, CXA, FOX, NIT, SXT  5/12 
101277-1 A. baumannii AMP, CXM, CXA, FOX, NIT, SXT  6/14 
502307-2 A. baumannii AMP, AMC, CXA, FOX, IMP, MEM, NIT, SXT  7/13 
502307-1 A. baumannii AMP, AMC, CXA, FOX, IMP, MEM, NIT, SXT  7/13 
109201-1 A. baumannii AMP, CXM, CXA, FOX, CTX, CAZ, NIT, SXT  7/14 
102461-1 A. baumannii AMP, CXM, CXA, FOX, CTX, CAZ, NIT, SXT  7/14 
106906-2 P. putida AMP, AMC, CXM, CXA, FOX, CTX, MEM, TGC, NIT, SXT  10/14 
106906-4 P. putida AMP, AMC, CXM, CXA, FOX, CTX, MEM, TGC, NIT, SXT 10/14 
107029-1 P. luteola AMP, CXA, FOX, NIT, SXT  5/13 
No., Number; AMP, Ampicillin; AMC, Amoxicillin-clavulanic acid; CXM, Cefuroxime; CXA, Cefuroxime Axetil; FOX, 
Cefoxitin; CTX, Cefotaxime; CAZ, Ceftazidime; TGC, Tigecycline; NIT, Nitrofurantoin; SXT, Trimethoprim-
sulfamethoxazole  
4.4 Detection of ESBL- and carbapenemase-producing bacteria 
The results obtained by the combination disc test and modified hodge test were 
consistent with PCR results. 
4.4.1 Phenotypic identification 
The production of ESBLs among Enterobacteriaceae (n= 17) was confirmed in 14 
(82.4%) isolates by the combination disc test (CDT) (Table 14). Using the CDT, 
cefotaxime with cefotaxime-clavulanate detected ESBLs in 100% (n= 14) of the isolates 
resistant to cefotaxime and/or ceftazidime. Cefepime with cefepime-clavulanate 
detected ESBLs in 93% (13/14) of such isolates. The combination of ceftazidime and 
ceftazidime-clavulanate discs detected ESBLs production in 78.6% (11/14) of 
Enterobacteriaceae isolates. All Enterobacteriaceae (n= 17) and non-fermenting Gram-
negative bacilli (n= 22) were negative for the production of carbapenemase enzymes by 

















No., Number; MIC, Minimum inhibitory concentration; CTX, Cefotaxime; CAZ, Ceftazidime; 
FEP, Cefepime; CTX-CV, Cefotaxime and cefotaxime-clavulanate; CAZ-CV, Ceftazidime and 
ceftazidime-clavulanate; FEP-CV, Cefepime and cefepime-clavulanate; +, Positive test 
result; -, Negative test result. 
4.4.2 Genotypic detection 
Using the PCR- and sequencing-based method, 14 of 39 (36%) Gram-negative bacilli 
isolates were positive for ESBL genes. All the E. cloacae isolates (n= 5) were positive for 
ESBL genes. In addition, six K. pneumoniae and three E. coli isolates carried ESBL genes 
(Table 15). The PCR test detected ESBL genes in all cefotaxime and/or ceftazidime 
resistant Enterobacteriaceae, but not in resistant non-fermenters (Table 15). As with 
phenotypic test, carbapenemase genes were not detected among 39 isolates tested.   
 
Isolate no. Species 
MIC values (µg/mL)  Combination disc tests 
CTX CAZ FEP  CTX-CV CAZ-CV FEP-CV 
507393-2 E. cloacae 8 ≥ 64 ≤ 1  + + + 
507394-1 E. cloacae 8 ≥ 64 ≤ 1  + + + 
506261-1 E. cloacae 4 16 ≤ 1  + + + 
506430-1 E. cloacae 4 16 ≤ 1  + + + 
104650-3 E. cloacae  4 16 ≤ 1  + + + 
101870-1 E. coli ≤ 1 ≤ 1 ≤ 1  - - - 
507214-1 E. coli ≤ 1 ≤ 1 ≤ 1  - - - 
502192-1 E. coli 4 ≤ 1 ≤ 1  + - + 
102461-4 E. coli ≥ 64 4 8  + - - 
307338-1 E. coli  ≥ 64 4 16  + - + 
106906-3 K. pneumoniae ≤ 1 ≤ 1 ≤ 1  - - - 
509599-1 K. pneumoniae ≥ 64 16 2  + + + 
506433-1 K. pneumoniae ≥ 64 8 2  + + + 
501940-1 K. pneumoniae ≥ 64 4 2  + + + 
502317-1 K. pneumoniae ≥ 64 16 2  + + + 
102461-2 K. pneumoniae ≥ 64 ≥ 64 16  + + + 





Table 15. Detection of ESBLs among Gram-negative bacilli by phenotypic and PCR 
methods 
Name of species 
(total) 
No. of isolates resistant 
to cefotaxime and/or 
ceftazidime (%) 
No. of isolates positive 
for ESBL by Combination 
Disc Test (%) 
No. of isolates 
positive for ESBL 
by PCR (%) 
E. cloacae (5) 5 (100) 5 (100) 5 (100) 
E. coli (5) 3 (60.0) 3 (60.0) 3 (60.0) 
K. pneumoniae (7) 6 (85.7) 6 (85.7) 6 (85.7) 
A. baumannii (10) 2 (20.0) 0 0 
P. putida (2) 2 (100) 0 0 
P. luteola (1) 0 0 0 
A. ursingii (2) 0 0 0 
S. maltophilia (4) 0 0 0 
C. pauculus (1) 0 0 0 
Total (39) 18 (46.2) 14 (35.9) 14 (35.9) 
4.5 Diversity of targeted beta-lactamase genes among Enterobacteriaceae 
Amplification and sequencing of the full length PCR products identified six beta-
lactamase genes; blaCTX-M-15, blaCTX-M-14, blaSHV-12, blaSHV-5, blaSHV-11 and blaTEM-1. Among 17 
Enterobacteriaceae, 14 (82.4%) carried ESBL genes, comprising of six blaCTX-M-15, three 
blaCTX-M-14, three blaSHV-12 and two blaSHV-5 genes (Table 16). The following narrow-
spectrum beta-lactamase (NSBL) genes were also detected: ten blaTEM-1 and six blaSHV-11 
genes. All ESBL-producing isolates possessed only one of the targeted ESBL genes. The 
blaCTX-M-15 gene was detected in all six resistant K. pneumoniae isolates only. This gene 
was detected in combination with the following NSBLs: blaCTX-M-15 + blaSHV-11 + blaTEM-1 
(n= 3), blaCTX-M-15 + blaSHV-11 (n= 2) and blaCTX-M-15 + blaTEM-1 (n= 1). One ESBL-negative K. 
pneumoniae isolate carried blaSHV-11 gene. All three ESBL-positive E. coli isolates carried 
both blaCTX-M-14 and blaTEM-1 genes. The blaSHV-type ESBL genes were not detected in K. 
pneumoniae and E. coli isolates. Of five ESBL-positive E. cloacae isolates, three 








Table 16. Distribution of ESBL and NSBL enzymes among Enterobacteriaceae 
  
4.6 Faecal carriage of ESBL-producing bacteria 
The prevalence of maternal faecal carriage of ESBL-producing bacteria at delivery was 
4.4% (4/90); (95% confidence interval (CI): 1.5% - 10.2%), and that of infants at birth 
Isolate no. Species 
Beta-lactamase contents 
Participant Location Time-point 
ESBL NSBL(s) 
507393-2 E. cloacae SHV-5 None Mother Mbekweni Delivery 
507394-1 E. cloacae SHV-5 None Infant Mbekweni Birth 
506261-1 E. cloacae SHV-12 TEM-1 Infant Mbekweni Birth 
506430-1 E. cloacae SHV-12 TEM-1 Infant Mbekweni Birth 
104650-3 E. cloacae  SHV-12 TEM-1 Infant Mbekweni 5 – 12 weeks 
101870-1 E. coli None None Infant Mbekweni 5 – 12 weeks 
507214-1 E. coli None None Mother Mbekweni Delivery 
502192-1 E. coli CTX-M-14 TEM-1 Mother TC Newman Delivery 
102461-4 E. coli CTX-M-14 TEM-1 Infant Mbekweni 20 – 28 weeks 
307338-1 E. coli  CTX-M-14 TEM-1 Infant Mbekweni 20 – 28 weeks 
106906-3 K. pneumoniae None SHV-11 Infant Mbekweni 20 – 28 weeks 
509599-1 K. pneumoniae CTX-M-15 SHV-11, TEM-1 Infant Mbekweni Birth 
506433-1 K. pneumoniae CTX-M-15 TEM-1 Mother TC Newman Delivery 
501940-1 K. pneumoniae CTX-M-15 SHV-11, TEM-1 Infant TC Newman 5 – 12 weeks 
502317-1 K. pneumoniae CTX-M-15 SHV-11, TEM-1 Mother Mbekweni Delivery 
102461-2 K. pneumoniae CTX-M-15 SHV-11 Infant Mbekweni 20 – 28 weeks 
303200-1 K. pneumoniae CTX-M-15 SHV-11 Infant TC Newman 5 – 12 weeks 
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was 3.5% (4/116); (95% CI: 1.2% - 8.0%). The infant faecal carriage at 5-12 and 20-28 
weeks of age was 4.4% (3/68); (95% CI: 1.3% - 11.3%) and 5.7% (2/35); (95% CI: 1.2% 
- 17.1%), respectively. The mothers were colonized with CTX-M-15-producing K.
pneumoniae (n= 2), SHV-5-producing E. cloacae (n= 1) and CTX-M-14-producing E. coli 
(n= 1). Three out of four infants at birth were colonized with E. cloacae isolates which 
possessed either blaSHV-12 (n= 2) or blaSHV-5 (n= 1) gene. One of the four infants was 
colonized with a blaCTX-M-15 carrying K. pneumoniae isolate (Table 16). At birth, only one 
mother-infant pair was ESBL-positive with SHV-5-producing E. cloacae isolates. Two of 
the three infants at 5-12 weeks were colonized with CTX-M-15-positive K. pneumoniae 
isolates. Longitudinal carriage of ESBL-producers was observed only in one infant who 
had SHV-12-producing E. cloacae, at birth and 5-12 weeks. Furthermore, only two 
children carried ESBL-producers at 20-28 weeks. One of the two children was colonized 
with CTX-M-14-producing E. coli isolate. The other child had both E. coli (blaCTX-M-14) and 
K. pneumoniae (blaCTX-M-15) and was the only participant being colonized by more than
one ESBL-producer. 
4.7 Antibiotic susceptibility pattern of ESBL-producing Enterobacteriaceae 
We observed very high rates of resistance to different antibacterial agents. All ESBL-
producing Enterobacteriaceae (n= 14) were multi-resistant to five or more classes of 
antibiotics. 
In this study, of the 14 ESBL-producing Enterobacteriaceae isolates examined, 64.3%, 
64.3%, 78.6%, 85.7% and 92.9% of the isolates were susceptible to cefoxitin, cefepime, 
tigecycline, piperacillin-tazobactam and ciprofloxacin, respectively (Table 17). Low 
susceptibility rates were also observed for amoxicillin-clavulanic acid (21.4%), 
nitrofurantoin (21.4%), ceftazidime (28.6%) and gentamicin (42.9%). All 14 ESBL-PE 
isolates were susceptible to ertapenem, meropenem, imipenem, amikacin and colistin. 
Furthermore, all the ESBL-producers were resistant to ampicillin, cefotaxime and 
trimethoprim-sulfamethoxazole (Figure 13).  
The 50% minimum inhibitory concentration (MIC50) for cefotaxime (64 µg/mL) among 
all ESBL-PE isolates was higher than that for ceftazidime (16 µg/mL) (Table 17). Four of 
the six CTX-M-15-producing K. pneumoniae isolates showed higher MICs for cefotaxime 





cefotaxime and ceftazidime (Figure 14). One CTX-M-15-producing K. pneumoniae isolate 
was susceptible to ceftazidime (MIC 4 µg/mL) (Figure 14). Of note, three cefepime-
resistant isolates were co-resistant to tigecycline (Table 11). Of the three CTX-M-14-
positive E. coli isolates, one had a low MIC (4 µg/mL) for cefotaxime and the other two 
had the MICs of ≥ 64 µg/mL. However, all three were susceptible to ceftazidime (Figure 
15). Furthermore, all five ESBL-positive E. cloacae isolates were resistant to both 
cefotaxime and ceftazidime and showed higher MICs for ceftazidime than for cefotaxime 
(Figure 16). Two SHV-5-producing E. cloacae isolates had higher MICs for both 
ceftazidime (≥ 64 µg/mL) and cefotaxime (8 µg/mL), whereas three SHV-12-producing 









Number (%) of 
resistant 
isolates 
Number (%) of 
intermediate 
isolates 




MIC50 MIC90 MICs range 
Ampicillin ≤ 8 14 (100) 0.0 0.0 32 32 32 – 32 
Amoxicillin/Clavulanic acid ≤ 8 6 (42.9) 5 (35.7) 3 (21.4) 16 32 4 – 32 
Piperacillin/Tazobactam ≤ 16 0.0 2 (14.3) 12 (85.7) 4 32 4 – 32 
Cefuroxime ≤ 8 13 (92.9) 1 (7.1) 0.0 64 64 16 – 64 
Cefuroxime axetil ≤ 4 13 (92.9) 1 (7.1) 0.0 64 64 16 – 64 
Cefoxitin ≤ 8 5 (35.7) 0.0 9 (64.3) 4 64 4 – 64 
Cefotaxime ≤ 1 14 (100) 0.0 0.0 64 64 4 – 64 
Ceftazidime ≤ 4 9 (64.3) 1 (7.1) 4 (28.6) 16 64 1 – 64 
Cefepime ≤ 2 3 (21.4) 2 (14.3) 9 (64.3) 2 16 1 – 16 
Ertapenem ≤ 0.5 0.0 0.0 14 (100) 0.5 0.5 0.5 – 0.5 
Imipenem ≤ 1 0.0 0.0 14 (100) 0.25 0.25 0.25 – 0.5 
Meropenem ≤ 1 0.0 0.0 14 (100) 0.25 0.25 0.25 – 0.25 
Amikacin ≤ 16 0.0 0.0 14 (100) 2 16 2 – 16 
Gentamicin ≤ 4 8 (57.1) 0.0 6 (42.9) 16 16 1 – 16 
Ciprofloxacin ≤ 1 0.0 1 (7.1) 13 (92.9) 0.25 1 0.25 – 2 
Tigecycline ≤ 1 3 (21.4) 0.0 11 (78.6) 1 2 0.25 - 2 
Nitrofurantoin ≤ 32 5 (35.7) 6 (42.9) 3 (21.4) 64 128 16 – 128 
Colistin ≤ 2 0.0 0.0 14 (100) 0.5 0.5 0.5 – 2 
Trimethoprim/Sulfamethoxazole ≤ 2 14 (100) 0.0 0.0 384 384 20 – 320 
MIC, Minimum inhibitory concentration; MIC50, Minimum inhibitory concentration required to inhibit the growth of 50% of organisms. MIC90, Minimum 








Figure 13. Susceptibility categorization of 14 ESBL-producing Enterobacteriaceae isolates to 19 
antibiotics by MICs determination.  
AMP, Ampicillin; AMC, Amoxicillin + clavulanic acid; TZP, Piperacillin-tazobactam; CXM, Cefuroxime; CXA, 
Cefuroxime Axetil; FOX, Cefoxitin; CTX, Cefotaxime; CAZ, Ceftazidime; FEP, Cefepime; ETP, Ertapenem; 
IPM, Imipenem; MEM, Meropenem; AMK, Amikacin; GEN, Gentamicin; CIP, Ciprofloxacin; TGC, 
Tigecycline; NIT, Nitrofurantoin; COL, Colistin; SXT, Trimethoprim-sulfamethoxazole. Findings were 


























Figure 14. Minimum inhibitory concentration (MIC) for cefotaxime (CTX) and 
ceftazidime (CAZ) in six CTX-M-15-producing K. pneumoniae isolates. 
 
 
Figure 15. Minimum inhibitory concentration (MIC) for cefotaxime (CTX) and 












Figure 16. Minimum inhibitory concentration (MIC) for cefotaxime (CTX) and 
ceftazidime (CAZ) in SHV-producing E. cloacae isolates.  
4.8 Comparative phenotypic testing for ESBLs detection 
Based on the combination disc test, cefotaxime with cefotaxime-clavulanate detected 
the production of ESBLs in six K. pneumoniae, three E. cloacae, three E. coli and two E. 
cloacae isolates harbouring blaCTX-M-15, blaSHV-12, blaCTX-M-14, and blaSHV-5 genes, 
respectively (Table 18). Ceftazidime with ceftazidime-clavulanate could not detect 
ESBLs in all three blaCTX-M-14-carrying E. coli isolates. In addition, the combination of 
cefepime and cefepime-clavulanate did not detect ESBLs production in one of the three 




Table 18: Comparison of ESBLs and the performance of phenotypic tests 
No., Number; MIC, Minimum inhibitory concentration; CTX, Cefotaxime; CAZ, Ceftazidime; FEP, Cefepime; CTX-CV, Cefotaxime and 
cefotaxime-clavulanate; CAZ-CV, Ceftazidime and ceftazidime-clavulanate; FEP-CV, Cefepime and cefepime-clavulanate; +, Positive test 
result; -, Negative test result. 
Isolate no. Species Beta-lactamase content 
Combination disc tests MIC values (µg/mL) 
CTX-CV CAZ-CV FEP-CV Cefotaxime Ceftazidime Cefepime 
507393-2 E. cloacae SHV-5 + + + 8 ≥ 64 ≤ 1 
507394-1 E. cloacae SHV-5 + + + 8 ≥ 64 ≤ 1 
506261-1 E. cloacae SHV-12, TEM-1 + + + 4 16 ≤ 1 
506430-1 E. cloacae SHV-12, TEM-1 + + + 4 16 ≤ 1 
104650-3 E. cloacae SHV-12, TEM-1 + + + 4 16 ≤ 1 
101870-1 E. coli None - - - ≤ 1 ≤ 1 ≤ 1 
507214-1 E. coli None - - - ≤ 1 ≤ 1 ≤ 1 
502192-1 E. coli CTX-M-14, TEM-1 + - + 4 ≤ 1 ≤ 1 
102461-4 E. coli CTX-M-14, TEM-1 + - - ≥ 64 4 8 
307338-1 E. coli CTX-M-14, TEM-1 + - + ≥ 64 4 16 
106906-3 K. pneumoniae SHV-11 - - - ≤ 1 ≤ 1 ≤ 1 
509599-1 K. pneumoniae CTX-M-15, SHV-11, TEM-1 + + + ≥ 64 16 2 
506433-1 K. pneumoniae CTX-M-15, TEM-1 + + + ≥ 64 8 2 
501940-1 K. pneumoniae CTX-M-15,  SHV-11, TEM-1 + + + ≥ 64 4 2 
502317-1 K. pneumoniae CTX-M-15,  SHV-11, TEM-1 + + + ≥ 64 16 2 
102461-2 K. pneumoniae CTX-M-15, SHV-11 + + + ≥ 64 ≥ 64 16 





4.9 Risk factors associated with the faecal carriage of ESBL-producing 
bacteria in infants at birth 
A univariate analysis comparing ESBL-positive and ESBL-negative infants showed that 
being born to HIV-positive mother, being born via elective caesarean section and 
administration of medication before discharge were positively associated with ESBL 
faecal carriage at birth (Table 19). In contrast, breastfeeding prior to discharge was 
negatively associated with ESBL faecal carriage. In addition, maternal hospitalization in 
the previous two years, admission to nursery, female gender and birth via emergency 
caesarean section were associated with ESBL carriage among infants, but these 
associations were not statistically significant. The associations were not calculated for 
the location, maternal ethnicity, vaginal vacuum delivery and supplement 
administration prior to discharge due to zero positivity (Table 19). Robust multivariate 













Table 19. Risk factors for ESBL carriage in 90 infants at birth: univariate analysis 
Variable No. ESBL-positive (%) Risk ratio [95% CI]  P value 
Gender      
 Male 49 2 (4.1) 1.0    
 Female 41 2 (4.9) 1.2 [0.18 – 8.12]  0.432 
Location      
 Mbekweni 41 4 (9.8) -   
          TC Newman 49 0 (0) -   
Maternal HIV status      
 Negative 71 1 (1.4) 1.0   
 Positive 19 3 (15.8) 11.3 [1.23 - 101.8]  0.015 
Maternal hospitalization in the previous 
two years 
     
 No 84 3 (3.6) 1.0   
 Yes 6 1 (16.7) 4.7 [0.57 - 38.4]  0.133 
Maternal ethnicity      
 Black African 40 4 (10) - 
 Mixed race 50 0 (0) -   
Mode of delivery      
 Normal vaginal 74 2 (2.7) 1.0   
 Elective caesarean section 2 1 (50) 18.5 [2.6 - 129.6]  0.039 
 Emergency caesarean section 13 1 (7.7) 2.8 [0.3 - 29.2]  0.223 
 Vaginal vacuum 1 0 (0) -   
Place of admission immediately after birth      
 Roomed with the mother 83 3 (3.6) 1.0   
 Nursery  7 1 (14.3) 3.95 [0.47 - 33.2]  0.155 
Medication before discharge      
 No 66 1 (1.5) 1.0   
 Yes 24 3 (12.5) 8.25 [0.90 - 75.5]  0.030 
Supplement before discharge      
 No 83 4 (4.8) -   
 Yes 7 0 (0) -   
Breastfeeding prior discharge      
 No 9 3 (33.3) 1.0   
 Yes 81 1 (1.2) 0.08 [0.01 – 0.31]  0.001 






4.10 Molecular typing by DNA macro-restriction analysis of selected beta-
lactamase-producing bacteria using PFGE 
The genomic DNA from seven K. pneumoniae and five E. cloacae isolates was digested 
with XbaI (Figure 17) and SpeI (Figure 18) and analyzed by PFGE.  
 
 
Figure 17. Pulsed-field gel electrophoresis of XbaI-digested genomic DNA from seven K. pneumoniae and 
five E. cloacae isolates.  
Lanes 1, 6, 11 and 17: PFGE lambda marker, lane 10: K. pneumoniae ATCC BAA 1705 control. Seven K. 
pneumoniae isolates in the following lanes; lane 2: 106906-3, lane 3: 502317-1, lane 4: 102461-2, lane 
5: 509599-1, lane 7: 303200-1, lane 8: 506433-1, lane 9: 501940-1. Five E. cloacae isolates in the 










Figure 18. Pulsed-field gel electrophoresis of SpeI-digested genomic DNA from seven K. pneumoniae and 
five E. cloacae isolates.  
Lanes 1, 6, 11 and 17: PFGE lambda marker, lane 10: K. pneumoniae ATCC BAA 1705 control. Seven K. 
pneumoniae isolates in the following lanes; lane 2: 106906-3, lane 3: 502317-1, lane 4: 102461-2, lane 
5: 509599-1, lane 7: 303200-1, lane 8: 506433-1, lane 9: 501940-1. Five E. cloacae isolates in the 
following lanes; lane 12: 104650-3, lane 13: 506261-1, lane 14: 507393-2, lane 15: 507394-1, lane 16: 
506430-1. 
4.10.1 Genotypic relatedness of ESBL-producing K. pneumoniae isolates 
The PFGE fingerprint profiling of seven K. pneumoniae isolates revealed six different 
PFGE patterns, A1, A2, B1, C1, D1 and E1 (Figures 19 and 20).  
PFGE-XbaI analysis identified only one PFGE cluster composed of three K. pneumoniae 
isolates (102461-2, 303200-1 and 106906-3) sharing ≥ 80% PFGE banding pattern 





pattern similarity. Isolate 102461-2 was identified in stool of 24 week old child from 
Mbekweni area and isolate 303200-1 in stool of 26 week old child from TC Newman 
area. These two isolates (102461-2 and 303200-1) produced both CTX-M-15 and SHV-
11, and had the same MICs for all tested (n= 19) antibiotics (Table 9). 
4.10.2 Genotypic relatedness of ESBL-producing E. cloacae isolates 
Both PFGE-XbaI and PFGE-SpeI analysis revealed two clusters (Figures 21 and 22). 
Cluster one contained two isolates (507393-2 and 507394-1), and cluster two contained 
three isolates (104650-3, 506261-1 and 506430-1). PFGE-XbaI analysis revealed three 
PFGE patterns (A1, A2 and B1), whereas PFGE-SpeI revealed only two PFGE patterns 
(A1 and B1).  
Two SHV-5-producing E. cloacae isolates (507393-2 and 509394-1) showed 100% PFGE 
pattern similarity by PFGE-SpeI analysis. These isolates (507393-2 and 509394-1) were 
recovered at birth from a mother-infant pair from Mbekweni area. In addition, these 
isolates (507393-2 and 509394-1) had the same resistance profile. All three E. cloacae 
isolates positive for both SHV-12 and TEM-1 enzymes (506261-1, 104650-3 and 
506430-1) were 100% similar by both PFGE-XbaI and PFGE-SpeI analysis. Isolates 
506261-1 (at birth) and 104650-3 (eight week old) were isolated from the same infant 
from Mbekweni area. Isolate 506430-1 was isolated from a different infant at birth, also 










Isolate no. Species Beta-lactamases PFGE Location Participant Time-point 
102461-2 K. pneumoniae CTX-M-15, SHV-11 A1 Mbekweni Infant 20-28 weeks 
303200-1 K. pneumoniae CTX-M-15, SHV-11 A1 TC Newman Infant 5-12 weeks 
106906-3 K. pneumoniae SHV-11 A2 Mbekweni Infant 20-28 weeks 
502317-1 K. pneumoniae CTX-M-15, SHV-11, TEM-1 B1 Mbekweni Mother Delivery 
506433-1 K. pneumoniae CTX-M-15, TEM-1 C1 TC Newman Mother Delivery 
509599-1 K. pneumoniae CTX-M-15, SHV-11, TEM-1 D1 Mbekweni Infant Birth 
501940-1 K. pneumoniae CTX-M-15, SHV-11, TEM-1 E1 TC Newman Infant 5-12 weeks 
Figure 19: Pulsed-field gel electrophoresis (PFGE)-XbaI analysis of seven K. pneumoniae isolates: one SHV-11-producing K. pneumoniae and six CTX-M-15-
producing K. pneumoniae isolates.  














Isolate no. Species Beta-lactamases PFGE Location Participant Time-point 
102461-2 K. pneumoniae CTX-M-15, SHV-11 A1 Mbekweni Infant 20-28 weeks 
303200-1 K. pneumoniae CTX-M-15, SHV-11 A1 TC Newman Infant 5-12 weeks 
501940-1 K. pneumoniae CTX-M-15, SHV-11, TEM-1 A2 TC Newman Infant 5-12 weeks 
106906-3 K. pneumoniae SHV-11 B1 Mbekweni Infant 20-28 weeks 
506433-1 K. pneumoniae CTX-M-15, TEM-1 C1 TC Newman Mother Delivery 
502317-1 K. pneumoniae CTX-M-15, SHV-11, TEM-1 D1 Mbekweni Mother Delivery 
509599-1 K. pneumoniae CTX-M-15, SHV-11, TEM-1 E1 Mbekweni Infant Birth 
Figure 20: Pulsed-field gel electrophoresis (PFGE)-SpeI analysis of seven K. pneumoniae isolates: one SHV-11-producing K. pneumoniae and six CTX-M-15-
producing K. pneumoniae isolates.  








Isolate no. Species Beta-lactamases PFGE Location Participant Time-point 
507393-2 E. cloacae SHV-5 A1 Mbekweni Mother Delivery 
509394-1 E. cloacae SHV-5 A2 Mbekweni Infant Birth 
104650-3 E. cloacae SHV-12, TEM-1 B1 Mbekweni Infant 5-12 weeks 
506261-1 E. cloacae SHV-12, TEM-1 B1 Mbekweni Infant Birth 
506430-1 E. cloacae SHV-12, TEM-1 B1 Mbekweni Infant Birth 
Figure 21: Pulsed-field gel electrophoresis (PFGE)-XbaI analysis of five E. cloacae isolates: two SHV-5-producing E. cloacae and three SHV-12-
producing E. cloacae isolates.  








Isolate no. Species Beta-lactamases PFGE Location Participant Time-point 
507393-2 E. cloacae SHV-5 A1 Mbekweni Mother Delivery 
509394-1 E. cloacae SHV-5 A1 Mbekweni Infant Birth 
104650-3 E. cloacae SHV-12, TEM-1 B1 Mbekweni Infant 5-12 weeks 
506261-1 E. cloacae SHV-12, TEM-1 B1 Mbekweni Infant Birth 
506430-1 E. cloacae SHV-12, TEM-1 B1 Mbekweni Infant Birth 
Figure 22: Pulsed-field gel electrophoresis (PFGE)-SpeI analysis of five E. cloacae isolates: two SHV-5-producing E. cloacae and three SHV-12-







5. Discussion  
The prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing 
Enterobacteriaceae in healthy individuals in the community is largely unknown.13,227 
However, such organisms are now distributed worldwide and their prevalence is 
increasing in community settings.13,41,45,60,126,319,378 This study, nested within a birth-
cohort study conducted in Drakenstein sub-district (Western Cape Province, South 
Africa) aimed to determine the prevalence and genetic characteristics and relatedness 
of ESBL- and carbapenemase-producing Enterobacteriaceae in stools from healthy 
infants of less than one years of age and their mothers, and to determine the risk factors 
associated with their carriage. The present study found that 4.4% of the mothers 
carried ESBL-PE in their stools at delivery. This rate is similar to the 3.7%,36 and 
4.3%,379 reported among Spanish and Moroccan healthy adults, respectively. In 
contrast, the maternal ESBL-PE faecal carriage rate observed in our study was higher 
than the 1.5% reported in Brazil,380 and 2.4% in Lebanon,381  but it was lower than 7% 
reported in China,195 8% in Israel,57 and 10% in Madagascar,20 among  healthy adults. 
The ESBL faecal carriage in pregnant women in this study is of specific concern, as they 
may transfer the ESBL-producing bacteria to the infants. In this study, the infant ESBL-
PE faecal carriage at birth was 3.5%. This carriage rate is probably a result of early 
vertical transmission from the mother-to-infant at delivery.358,382 All colonized infants at 
birth were born to the mothers from Mbekweni area and none from TC Newman area. 
This observation could suggest that the hospital was unlikely to be the source of ESBL-
producing bacteria in this study. However, their acquisition from the hospital setting 
cannot be disregarded.383 The ESBL faecal carriage in our study is lower than the 9% 
reported in India among healthy low birth weight (LBW) neonates at day one.359  
The present study is the first to detect ESBL-producing Enterobacteriaceae in human 
meconium samples in Africa. The ESBL-producing Enterobacteriaceae was not detected 
in meconium in a study conducted in France.358 The infant ESBL-PE faecal carriage of 
4.4% at 5-12 weeks in our study was lower than 31% reported in India among LBW 
infants at day 60 (8.6 weeks).359 The infant ESBL faecal carriage at 20-28 weeks was 
5.7%. This rate is comparable to 4.6%,47 and 6.4%,384 reported among healthy French 
children of ages between 13 and 174 weeks. In contrast, it is higher than 1.7% reported 





from 26 to 287 weeks). The increase in ESBL faecal carriage from 3.5% at birth to 5.7% 
at 20-28 weeks might be due to an increase time of exposure to maternal environment, 
oral and skin flora.358,359,382 However, the increase in ESBL faecal carriage might simply 
reflect sampling error due to small numbers.  
No carbapenemase-producing organisms were detected in mothers and infants in this 
study. Our findings are in agreement to what has been recently reported in Switzerland, 
where no carbapenemase-producing organisms were found among healthy adults in the 
community.17 Nevertheless, a study conducted in an Indian community found that one 
in 75 infants was colonized by KPC-2-producing Enterobacter aerogenes isolate.359   
The ChromID ESBL and CARBA media were not perfectly selective for ESBL- and 
carbapenemase-producing isolates, respectively. Non-ESBL- and non-carbapenemase-
producers that grew on these media were mainly non-fermenting Gram-negative bacilli. 
These observations are probably due to isolates harbouring mechanisms of resistance 
other than ESBL and carbapenemase production.387 Therefore, complementary tests are 
required to confirm the production of ESBLs and carbapenemases in isolates growing 
on these partially selective media.388 Furthermore, prolonged incubation to 48 hours 
did not have an effect on the recovery of ESBL-producing bacteria. This was also 
observed by Glupczynski and colleagues in a study conducted in Belgium.389 In contrast, 
a study conducted in France reported an increased recovery of ESBL-producers by 6% 
from 765 clinical samples after 48 hours of incubation.363 
The MIC values observed for cefotaxime and ceftazidime among our isolates are typical 
of ESBL-producers.330 We observed that a combination of cefotaxime and cefotaxime-
clavulanate was more effective in detecting ESBL-producing bacteria. The ability of the 
combination disc test to detect the production of ESBLs is excellent, and the sensitivity 
when using both cefotaxime and cefepime alone and in combination with clavulanic acid 
can reach up to 100%.316  Although ceftazidime with clavulanic acid detects most ESBL-
producers, it could not detect all ESBL-producing bacteria, especially CTX-M-producing 
isolates,159 as observed in this study. This might be due to the fact that most of the CTX-
M-type enzymes are more active against cefotaxime than ceftazidime.146  
Furthermore, most of ESBL-producing Enterobacteriaceae in this study were co-





trimethoprim-sulfamethoxazole and aminoglycosides has been shown to be common in 
ESBL-producers;2,390 and this led to increased usage of nitrofurantoin for treatment of 
urinary tract infections.391,392 High proportion of isolates resistant to nitrofurantoin 
(78.6%) in our study is of concern. This rate is higher than reported in other studies, 
including in Iran (6%),393 and Cameroon (34.5%).227 Nitrofurantoin is an alternative, 
rather than a first-line, therapeutic agent for treatment of urinary tract infections 
caused by ESBL-producers.393,395,396 Moreover, tigecycline-resistance (3/14; 21.4%) 
observed among CTX-M-15-positive K. pneumoniae isolates in our study is also 
worrisome. Resistance to tigecycline among K. pneumoniae ranged from 0% to 11.5% in 
different studies.397–400 Tigecycline remains as one of the few therapeutic options for 
infections due to ESBL-producing isolates;397,400 therefore, the usage and close 
monitoring of its resistance are important.401 The ESBL-producing isolates in our study 
were completely susceptible to ertapenem, meropenem, imipenem, amikacin and 
colistin. Carbapenems are the first line drugs for the treatment of severe infections 
caused by ESBL-producing bacteria.27  
In this study, the bacterial species responsible for ESBLs production were the K. 
pneumoniae, E. cloacae and E. coli isolates. CTX-M enzymes were the most prevalent 
ESBLs in our isolates and CTX-M-15 in K. pneumoniae isolates was the most common 
enzyme. This is in accordance with what has been reported in other studies and support 
the evidence of CTX-M as the most prevalent type of ESBL in community settings 
worldwide.30,48,150,152,186,385 Unlike most CTX-M-type enzymes, CTX-M-15 is associated 
with high level of resistance to both cefotaxime and ceftazidime in K. pneumoniae and 
other Enterobacteriaceae species.402 This was also observed in CTX-M-15-producing K. 
pneumoniae isolates in our study. Of note, in this study, ESBL-producing E. coli isolates 
carried both CTX-M-14 and TEM-1 enzymes and not CTX-M-15, known to be effectively 
disseminated by E. coli isolates worldwide.43 CTX-M-14-producing E. coli isolates have 
been isolated from several community hospitals in the Cape Town metropolitan area, 
and 42.9% of them co-produced TEM-1 and belonged to ST 131, an ST-type clone which 
is circulating in the community settings worldwide.43,403 CTX-M-14 enzyme is the most 
common CTX-M-type in Asia,195–197 and only few studies have reported its occurrence in 
Africa.231,403–406 Studies in Canada and USA showed that CTX-M-14-producing E. coli had 





infections.407,408 TEM-type ESBLs were not detected in all Enterobacteriaceae isolates in 
this study. In South Africa, the TEM-type ESBLs are commonly identified among isolates 
in hospital settings.223–225 The detection of genes encoding blaSHV-type enzymes in most 
of the K. pneumoniae isolates confirms that they are ubiquitous in such bacterial 
species.409 Other important findings in this study were the occurrence of SHV-12 and 
SHV-5 enzyme in E. cloacae isolates. These findings probably suggest the simultaneous 
community spread of SHV-12 and SHV-5 genotypes in our setting. Our findings are in 
accordance with the reports from Spain,410 Bosnia and Herzegovina,411 Egypt,141 and 
Morocco,36 suggesting that SHV-type ESBLs could be as widespread in community 
settings as CTX-M enzymes.36  
In this study, the different PFGE profiles detected among six CTX-M-15-producing K. 
pneumoniae isolates indicates that the spread of blaCTX-M-15 gene was not due to a single 
clone, but rather likely due to horizontal transfer of blaCTX-M-15-carrying plasmids 
between isolates with different genetic background.141 Furthermore, several distinct 
PFGE profiles suggest possible carriage of the blaCTX-M-15 gene on different antibiotic 
resistance plasmids.161,412 Two CTX-M-15-producing K. pneumoniae isolates (102461-2 
and 303200-1) with similar DNA fingerprint profiles from infants in different areas is of 
interest and may point to an unidentified epidemiological link. Two clones were 
observed in five SHV-producing E. cloacae isolates in individuals from Mbekweni area. 
These observations infer that blaSHV-12- and blaSHV-5-harbouring E. cloacae clones are 
already circulating in Mbekweni area. The CTX-M-15-producing K. pneumoniae, SHV-12- 
and SHV-5-producing E. cloacae clones from different locations or families may suggest 
inadequate hygiene conditions, contamination at the same source or the dissemination 
of such organisms through the environment as it has been previously described.413,414  
Several risk factors associated with colonization or infection with ESBL-producing 
bacteria in the community have been identified in different studies.20,415–418 In this 
study, due to the limited number of samples at the later time-points studied (5-12 and 
20-28 weeks), we only assessed the risk factors associated with the acquisition of ESBL-
producers in 90 mother-infant pairs sampled at birth. Infants born to HIV-positive 
mother were 11 times more likely to be carriers of ESBL-producing bacteria compared 
with those born to HIV-negative mothers. This finding likely reflects prior exposure of 





carriage and subsequently passed it on to the children. Our data also suggest that ESBL 
carriage in infants is significantly associated with mode of delivery. Infants born by 
elective caesarean section were 19 times more likely to be colonized by ESBL-producers 
compared to those delivered vaginally. Infants born by caesarean section are more 
exposed to the mother’s skin microbiota and bacteria from the hospital environment 
than those who are born vaginally.419,420 Another possible explanation could be the 
intrapartum use of antibiotics by mothers who had caesarean section.420 Caesarean 
section influences the composition of intestinal microbiota during the first three days of 
life.421 Previous use of antibiotics, especially the third generation cephalosporins, 
aminoglycosides, fluoroquinolones or trimethoprim-sulfamethoxazole has been 
associated with the faecal carriage of ESBL-producers in the community 
settings.227,383,422–427 The ESBL faecal carriage in our study was significantly associated 
with administration of medication prior to discharge [risk ratio (RR) 3.95, 95% CI 0.47 - 
33.2, P = 0.030]. Type of medication given to the infants before discharge was unknown 
and therefore this association could not be fully understood. Breastfeeding prior to 
discharge was a protective factor [RR 0.08, 95% CI 0.01 - 0.31, P = 0.001] (compared to 
those who were not breastfed) against colonization with ESBL-producing 
Enterobacteriaceae. The absence of breastfeeding has been associated with the faecal 
carriage of ESBL-producing organisms.428–430 Infants who are breastfed are unlikely to 
be colonized by ESBL-producers; therefore, possible role of breastfeeding as a 
protective factor requires further research. HIV exposure and absence of breastfeeding 
were associated with ESBL faecal carriage. Infants probably had not been breastfed 
prior to passing meconium and HIV-infected mothers are unlikely to breastfeed. 
Therefore, we could not determine, by multivariate analysis, which variable was 
independently associated with this carriage due to small numbers of ESBL-PE detected. 
In this study, higher rates of ESBL carriage were observed in participants (both mothers 
and infants) from Mbekweni area. At delivery, 4.9% (2/41) of the mothers from 
Mbekweni area, compare to 4.1% (2/49) from TC Newman area, were ESBL carriers. In 
infants, 9.1% (6/66) and 4% (2/50) of ESBL carriers at three different time-points were 
from Mbekweni and TC Newman, respectively. Such high rates of ESBL carriage in the 
mothers and infants from Mbekweni area might be partially explained by the fact that 





main risk factor associated with the carriage of ESBL-producers amongst healthy 
individuals in Madagascar.20 Another possible explanation can be the relatively poor 
sanitation in Mbekweni area, where sewage (possibly contaminated with ESBL-
producers) contaminates river water used for watering local agricultural products that 
are subsequently used for food. In Mbekweni area, a recent study has reported the 
detection of several bacterial species (K. pneumoniae, K. oxytoca, E. coli and E. cloacae) 
in water used for irrigational and recreational purposes from the Berg River.431  The 
latter study did not assess the production of ESBLs.431 In Norway, recreational 
swimming in freshwater has been associated with the acquisition of ESBL-producing 
bacteria.383 Moreover, the detection of ESBL-producers in environmental water samples 
has been previously reported elsewhere.422,432,433  
We found, in this study, that one infant was colonized with SHV-12-producing E. cloacae 
at birth and at eight weeks. The duration and persistence of ESBL faecal carriage can 
vary greatly.420,434 Therefore, long-term ESBL faecal carriage in infants may represent a 
significant reservoir for the spread of ESBL-producing Enterobacteriaceae to household 
members.420 Persistence colonization with ESBL-PE isolates has been described in 
Germany,435 and Sweden.436,437 This study also found that one ESBL-positive infant had 
an ESBL-positive colonized mother. PFGE showed that the SHV-5-producing E. cloacae 
isolates from the mother-infant pair were identical, suggesting that vertical 
transmission from the mother-to-child at delivery or antenatally was likely. This finding 
is in agreement with what has been reported in the literature.438 The maternal vagina, 
skin and breast milk which have been shown to be the potential source of ESBL-PE  
during or after birth,358,382 were not assessed in our study. Therefore, the acquisition of 
such organisms by the infants from the mothers who screened negative for faecal ESBL 
carriage cannot be excluded.358,382 
This study has some limitations. The study only assessed the risk factors associated 
with the acquisition of ESBL faecal carriage at birth due to limited data for other time-
points. The small sample size may limit also the power of the study to recognize other 
risk factors for acquisition of ESBL-producers; consequently, more studies with large 
sample size are needed to address this issue. Also, the ESBL faecal carriage might have 
been underestimated because not all the mothers or infants were sampled at all time-





child vertical transmission after birth could not be assessed. Due to insufficient amount 
of samples, we did not screen for ESBL and carbapenemase genes from the DNA 
extracted from stool samples. Culture-negative stool samples might contain DNA, with 
ESBL or carbapenemase genes, from non-viable or less abundant bacteria in the 
samples.50  
Plasmids are epidemiologically relevant DNA elements in ESBL transfer; therefore, their 
role and association with MLST sequence types need to be examined.439 In this study, 
MLST was not performed on ESBL-producers. Resistance determinants other than 
ESBLs and carbapenemases were not determined. This study only screened for the 
three common ESBL genes, thus compromising the detection of uncommon ESBL 
genes.159 Lastly, a large sample size is required to obtain more precise estimates of the 
prevalence and risk factors. Nevertheless, the results of this study contribute to an 
improved understanding of the epidemiology of ESBL- and carbapenemase-producing 









6. Conclusions and future direction 
In conclusion, this is the first study to detect ESBL-producing bacteria in human 
meconium samples in Africa, and raises questions on the source of such isolates and 
implications for the transmission of ESBL-producing bacteria in the community. This 
study also showed that faecal carriage of ESBL-PE among apparently healthy individuals 
is relatively common in our study setting, the Drakenstein sub-district. CTX-M- and SHV 
were the main enzymes circulating in our study setting. Person-to-person transmission 
might enhance their dissemination in the community settings,427 which would explain 
the mother-to-infant transmission observed in this study. ESBL faecal carriage is 
considered to be a risk factor for infections with such bacteria, leading to an increased 
usage of carbapenems,6,44 which may contribute to carbapenem resistance due to 
carbapenemases or porin loss with ESBL production.27 In addition, multidrug-resistant 
bacteria may be imported into the hospital settings; therefore, the spread of these 
organisms in community settings in South Africa merits further surveillance.440 Another 
important finding was the occurrence of SHV-12 and SHV-5 enzymes in the Drakenstein 
sub-district, South Africa. This may suggest that SHV-12 and SHV-5 could be widespread 
in our community, as it has been observed in Morocco,36 and Egypt.141 Further studies 
are needed to fully understand the epidemiology of SHV-type enzymes in the 
community settings. Furthermore, research on the persistence and duration of ESBL-PE 
carriage in the community is needed. Lastly, we did not detect carbapenemase-
producing organisms in the stool samples tested. Further research or continuous 
surveillance is important in order to anticipate future trends in the dissemination of 
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